EP3615007A1 - Pharmaceutical tablet composition comprising eltrombopag olamine - Google Patents
Pharmaceutical tablet composition comprising eltrombopag olamineInfo
- Publication number
- EP3615007A1 EP3615007A1 EP18711260.2A EP18711260A EP3615007A1 EP 3615007 A1 EP3615007 A1 EP 3615007A1 EP 18711260 A EP18711260 A EP 18711260A EP 3615007 A1 EP3615007 A1 EP 3615007A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- pharmaceutically acceptable
- eur
- lactose
- pharmaceutical tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DJMJHIKGMVJYCW-UHFFFAOYSA-N 2-aminoethanol 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid Chemical compound CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N DJMJHIKGMVJYCW-UHFFFAOYSA-N 0.000 title claims abstract description 168
- 229960001827 eltrombopag olamine Drugs 0.000 title claims abstract description 167
- 239000007916 tablet composition Substances 0.000 title claims abstract description 152
- 235000000346 sugar Nutrition 0.000 claims abstract description 68
- 150000008163 sugars Chemical class 0.000 claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 20
- 206010043554 thrombocytopenia Diseases 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 208000032467 Aplastic anaemia Diseases 0.000 claims abstract description 15
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims abstract description 15
- 238000011321 prophylaxis Methods 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 182
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 135
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 124
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 112
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 112
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 93
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 78
- 229960001375 lactose Drugs 0.000 claims description 78
- 239000008101 lactose Substances 0.000 claims description 78
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 74
- 239000008109 sodium starch glycolate Substances 0.000 claims description 74
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 74
- 239000003795 chemical substances by application Substances 0.000 claims description 70
- 239000011230 binding agent Substances 0.000 claims description 68
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 68
- 229940069328 povidone Drugs 0.000 claims description 68
- 238000002156 mixing Methods 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
- 235000019359 magnesium stearate Nutrition 0.000 claims description 56
- 229940057948 magnesium stearate Drugs 0.000 claims description 56
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 56
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 56
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 56
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 55
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 50
- 229960001021 lactose monohydrate Drugs 0.000 claims description 50
- 239000004480 active ingredient Substances 0.000 claims description 32
- 239000003085 diluting agent Substances 0.000 claims description 32
- 239000007884 disintegrant Substances 0.000 claims description 31
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 27
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 26
- 229960000913 crospovidone Drugs 0.000 claims description 25
- 238000005469 granulation Methods 0.000 claims description 25
- 230000003179 granulation Effects 0.000 claims description 25
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 25
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 23
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 23
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 23
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 18
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 18
- 235000010447 xylitol Nutrition 0.000 claims description 18
- 239000000811 xylitol Substances 0.000 claims description 18
- 229960002675 xylitol Drugs 0.000 claims description 18
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 18
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 17
- 229930091371 Fructose Natural products 0.000 claims description 17
- 239000005715 Fructose Substances 0.000 claims description 17
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 17
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 17
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 17
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 17
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 17
- -1 acetate-polyethylene Chemical group 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 229940032147 starch Drugs 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 238000005550 wet granulation Methods 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920000881 Modified starch Polymers 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001531 copovidone Polymers 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 229960001855 mannitol Drugs 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 229920000578 graft copolymer Polymers 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 6
- 239000004386 Erythritol Substances 0.000 claims description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 235000019414 erythritol Nutrition 0.000 claims description 6
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 6
- 229940009714 erythritol Drugs 0.000 claims description 6
- 239000000905 isomalt Substances 0.000 claims description 6
- 235000010439 isomalt Nutrition 0.000 claims description 6
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 6
- 235000010449 maltitol Nutrition 0.000 claims description 6
- 239000000845 maltitol Substances 0.000 claims description 6
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 6
- 229940035436 maltitol Drugs 0.000 claims description 6
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229960004977 anhydrous lactose Drugs 0.000 claims description 4
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 4
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical group COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract 1
- 229950004864 olamine Drugs 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 68
- 239000007941 film coated tablet Substances 0.000 description 59
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 56
- 229960001069 eltrombopag Drugs 0.000 description 39
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 35
- XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 description 26
- 238000005461 lubrication Methods 0.000 description 26
- 239000007888 film coating Substances 0.000 description 25
- 238000009501 film coating Methods 0.000 description 25
- 239000004615 ingredient Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 20
- 239000012535 impurity Substances 0.000 description 19
- 229920003072 Plasdone™ povidone Polymers 0.000 description 18
- 238000003860 storage Methods 0.000 description 16
- LQQUHOUXABUDJA-OUFJFOJPSA-N chembl461806 Chemical compound NCCO.CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 LQQUHOUXABUDJA-OUFJFOJPSA-N 0.000 description 15
- 239000000470 constituent Substances 0.000 description 15
- 230000001186 cumulative effect Effects 0.000 description 15
- 239000008187 granular material Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 229920003075 Plasdone™ K-29/32 polymer Polymers 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 235000013980 iron oxide Nutrition 0.000 description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 241000711549 Hepacivirus C Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229960003943 hypromellose Drugs 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 208000006154 Chronic hepatitis C Diseases 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000009506 drug dissolution testing Methods 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 208000010710 hepatitis C virus infection Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000007894 caplet Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 239000002491 polymer binding agent Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229940021945 promacta Drugs 0.000 description 2
- 238000010925 quality by design Methods 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 229960002063 sofosbuvir Drugs 0.000 description 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 2
- 238000013097 stability assessment Methods 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 235000019886 MethocelTM Nutrition 0.000 description 1
- LQQUHOUXABUDJA-UHFFFAOYSA-N NCCO.CC=1C=C(C=CC1C)N1N=C(C(C1=O)=NNC=1C(=C(C=CC1)C1=CC(=CC=C1)C(=O)O)O)C Chemical compound NCCO.CC=1C=C(C=CC1C)N1N=C(C(C1=O)=NNC=1C(=C(C=CC1)C1=CC(=CC=C1)C(=O)O)O)C LQQUHOUXABUDJA-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960005449 daclatasvir Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 229960001418 dasabuvir Drugs 0.000 description 1
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- BVAZQCUMNICBAQ-PZHYSIFUSA-N elbasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=C3O[C@H](N4C5=CC=C(C=C5C=C4C3=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)C=2C=CC=CC=2)=CN1 BVAZQCUMNICBAQ-PZHYSIFUSA-N 0.000 description 1
- 229960002007 elbasvir Drugs 0.000 description 1
- 229940039034 eltrombopag 12.5 mg Drugs 0.000 description 1
- 229940021929 eltrombopag 25 mg Drugs 0.000 description 1
- 229940021953 eltrombopag 50 mg Drugs 0.000 description 1
- 229940018288 eltrombopag 75 mg Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- OBMNJSNZOWALQB-NCQNOWPTSA-N grazoprevir Chemical compound O=C([C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCC1=NC3=CC=C(C=C3N=C1O2)OC)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C OBMNJSNZOWALQB-NCQNOWPTSA-N 0.000 description 1
- 229960002914 grazoprevir Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 description 1
- 229960002461 ledipasvir Drugs 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229940008015 lithium carbonate Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229920005690 natural copolymer Polymers 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229960000518 ombitasvir Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 1
- 229960002754 paritaprevir Drugs 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005596 polymer binder Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002091 simeprevir Drugs 0.000 description 1
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- FHCUMDQMBHQXKK-CDIODLITSA-N velpatasvir Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](C[C@@H](C2)COC)C=2NC(=CN=2)C=2C=C3C(C4=CC5=CC=C6NC(=NC6=C5C=C4OC3)[C@H]3N([C@@H](C)CC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)=CC=CC=C1 FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 description 1
- 229960000863 velpatasvir Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- composition comprising Eltrombopag Olamine
- the present invention relates to a pharmaceutical tablet composition comprising eltrombopag olamine and one or more reducing sugars, a production process therefore, a pharmaceutical tablet composition comprising eltrombopag olamine and one or more reducing sugars obtainable by the production process, a use / method of use of the pharmaceutical tablet compositions in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
- IDP immune iopathic thrombocytopenic purpura
- SAA acquired severe aplastic anaemia
- eltrombopag olamine is approved under the tradename Revolade ® comprising eltrombopag olamine in an amount corresponding to 12.5 mg, 25 mg, 50 mg, and 75 mg eltrombopag free acid in tablet form.
- eltrombopag olamine is approved under the tradename Promacta ® comprising eltrombopag olamine in an amount corresponding to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg eltrombopag free acid in tablet form.
- Revolade ® tablets are packed in Alu-Alu blisters, whereas Promacta ® tablets are packed in HDPE bottles.
- Revolade ® is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Revolade ® may be considered as second line treatment for adult non- splenectomised patients where surgery is contraindicated.
- ITP thrombocytopenic purpura
- Revolade ® is also indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
- HCV chronic hepatitis C virus
- Revolade ® is furthermore indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
- SAA severe aplastic anaemia
- an eltrombopag tablet composition is disclosed in example 6 which comprises in addition to 8.45 mg eltrombopag olamine, furthermore 1 12 mg microcrystalline cellulose, 70 mg lactose, 8 mg sodium starch glycolate and 2 mg magnesium stearate.
- eltrombopag olamine undergoes a Maillard reaction with respective pharmaceutically acceptable excipients, such as reducing sugars, e.g. lactose. It is known that eltrombopag olamine is degraded in presence of lactose and forms impurities, which can be measured in the pharmaceutical tablet composition. Mr.
- Kapsi one of the inventors of WO 2008/136843 A1 provided in the corresponding US examination of US 2010/0040684 A1 a declaration (in the context of the present application called "Kapsi declaration") disclosing experimental stability data for the use of the lactose containing eltrombopag tablet composition of example 6 in WO 03/098992 A2 in comparison to a tablet formulation, which is free of reducing sugars using mannitol instead.
- the eltrombopag olamine tablet formulation comprising lactose shows an "increase in degradation products when compared to the mannitol based formulation (4 fold difference in degradation products at 3 months" (see section Results on page 1 ).
- Mr. Kapsi followed that the "experimental data described herein demonstrates that the formulation described as Example 6 in publication WO 03/098992 A2 leads to a tablet formulation with a four-fold higher level of degradation products at 3 months and in my experience leads to an unacceptable tablet formulation".
- WO 2008/136843 A1 teaches to use diluents substantially free of reducing sugars, in particular using mannitol.
- the avoidance of reducing sugars as pharmaceutical excipient in an eltrombopag olamine pharmaceutical tablet is continued in WO 2012/121957 A1 and WO 2015/0121957 A2. It would, however, be desirable to provide an alternative solution for a stable eltrombopag olamine pharmaceutical tablet composition, wherein the degradation level of eltrombopag olamine is negligible and the pharmaceutical tablet composition fulfills the regulatory stability criteria for pharmaceutical tablets. Furthermore, it would be desirable that the pharmaceutical tablet composition is more economic in costs per unit and/or allows tuning one or more pharmaceutical technological aspects during the production process.
- a first aspect of the present invention relates to a pharmaceutical tablet composition
- a pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars
- the composition comprises or consists of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition or c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an intragranular composition and d) eltrombopag olamine in a therapeutically
- a second aspect of the present invention relates to an inventive pharmaceutical tablet composition for use in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
- IDP immune thrombocytopenic purpura
- SAA acquired severe aplastic anaemia
- a third aspect of the present invention relates to a process of production of an inventive pharmaceutical tablet comprising eltrombopag olamine as active ingredient and one or more pharma- ceutically acceptable excipients including one or more reducing sugars, characterized in that the process comprises the following steps: either a. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients, b. wet granulation of components mixed in step a) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, in a suitable amount to form an intragranular composition, c.
- a suitable granulation fluid preferably water or an aqueous solution of a binder
- step d mixing one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients to form an extragranular composition
- step c) mixing the extragranular composition of step c) with the intragranular composition of step b) to form a tablet composition
- step d) compressing the tablet composition of step d) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the intragranular phase and one or more reducing sugars in the extragranular phase, or f.
- reducing sugars preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally further one or more pharmaceutically acceptable excipients, g. wet granulation of components mixed in step f) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, to form an intragranular composition, h. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients to form an extragranular composition, i. mixing the extragranular composition of step h) with the intragranular composition of step g) to form a tablet composition, and j.
- a fourth aspect of the present invention relates to a pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the composition which comprises or consists of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition, or c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose,
- a fifth aspect of the present invention relates to a use of an inventive pharmaceutical tablet composition, wherein the pharmaceutical tablet composition is used in the manufacture of a medicament for the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
- IDP immune thrombocytopenic purpura
- SAA acquired severe aplastic anaemia
- a sixth aspect of the present invention relates to a method of treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA), comprising administering to a patient in need an inventive pharmaceutical tablet composition.
- IDP immune thrombocytopenic purpura
- SAA acquired severe aplastic anaemia
- the inventive pharmaceutical tablet comprising eltrombopag olamine in one granular composition (either intra- or extragranular) and one or more reducing sugars in a different granular composition (either extra- or intragranular) is not subjected to a substantial degradation of the active ingredient eltrombopag olamine in view of Maillard reactions with the reducing sugar and, thus, fulfills the regulatory stability requirements for commercializing the pharmaceutical eltrombopag olamine tablet (see example section Part E, tables 1 and 2).
- the inventive pharmaceutical tablet is stable over at least 6 months when stored preferably in Alu-Alu blisters at intermediate or long-term storage conditions, preferably at 25°C / 60% relative humidity (RH) and/or 40°C / 75 % RH.
- the inventive pharmaceutical tablet composition according to all aspects of the present invention comprises reducing sugars only in that granular composition (phase), which does not comprise the eltrombopag olamine constituent.
- the reducing sugar is present in the extragranular composition and in case the eltrombopag olamine is present in the extragranular composition, the reducing sugar is present in the intragranular composition.
- the experimental data provided in table 3 in Part E) of the example section shows that 75 wt.% or more, preferably more than 80 wt.%, more preferably more than 90 wt.% of eltrombopag olamine in the inventive pharmaceutical tablet composition is dissolved within 45 minutes in accordance with the regulatory standard test.
- inventive teaching namely by separating the eltrombopag olamine active ingredient and the reducing sugar in different granular compositions, it is possible to maintain the use of a reducing sugar as diluent constituent in the tablet formulation of eltrombopag olamine and at the same time achieve a suitable dissolution profile for the inventive pharmaceutical tablet composition.
- intragranular composition refers to tablet constituents which are wet granulated and thus forming granules to be further processed as intragranular composition / phase of the inventive pharmaceutical tablet composition.
- the intragranular tablet constituents comprise a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients
- the intragranular composition does not comprise a reducing sugar, e.g. lactose, as pharmaceutically acceptable excipi- ent.
- the intragranular composition comprises a reducing sugar, e.g. lactose and optionally one or more pharmaceutically acceptable excipients
- the intragranular composition does not comprise eltrombopag olamine.
- the "extragranular composition” is admixed with the granules of the intragranular composition and the mixture forms the basis for the tablet composition. This mixture is subsequently compressed to form the inventive pharmaceutical tablet composition.
- the extragranular composition comprises or consists of one or more reducing sugars and optionally one or more further pharmaceutical excipients then the extragranular composition does not comprise eltrombopag olamine.
- the extragranular composition comprises eltrombopag olamine and optionally one or more pharmaceutically acceptable excipients, then the extragranular composition does not comprise a reducing sugar, in particular lactose.
- the inventive pharmaceutical tablet composition comprises eltrombopag olamine as the active ingredient in a therapeutically effective amount and optionally one or more further active ingredients.
- eltrombopag olamine refers to an amorphous form or one or more polymorphic crystalline forms of eltrombopag olamine, wherein eltrombopag olamine has been defined hereinbefore as eltrombopag biseth- anolamine.
- eltrombopag olamine in particular polymorphic form I of eltrombopag olamine (cf. figure 28 of WO 2010/1 14943 A1 shows polymorphic form I of eltrombopag bisethanolamine) is used in accordance with all aspects and preferred embodiments of the present invention.
- the eltrombopag olamine is generally used exhibiting suitable particle sizes for formulating the inventive pharmaceutical tablet composition, wherein preferably the particle size distribution by volume (PSD) is 30 m or less for 90 Vol. % of the particles (D 0.9), 8 m or less for 50 Vol. % of the particles (D 0.5), and/or 2 ⁇ or less for 10 Vol. % of the particles (D 0.1 ).
- PSD particle size distribution by volume
- the particle size distribution by volume may be determined by use of the Malvern technique (by volume).
- the active ingredient eltrombopag olamine is used per tablet unit in an amount of 16.05 mg, 32.1 mg, 64.2 mg, 96.3 mg or 128.4 mg eltrombopag olamine (respectively corresponding to 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg eltrombopag free acid).
- the inventive pharmaceutical tablet composition is effective for use in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
- the inventive pharmaceutical tablet composition is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) in splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
- ITP thrombocytopenic purpura
- the inventive pharmaceutical tablet composition may also be considered as second line treatment for adult non-splenectomised patients where surgery is contraindicated.
- the inventive pharmaceutical tablet composition is preferably furthermore indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
- HCV chronic hepatitis C virus
- the inventive pharmaceutical tablet composition is preferably furthermore indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
- SAA severe aplastic anaemia
- suitable reducing sugars i.e. sugar constituents which generally may form a Maillard reaction with the active ingredient eltrombopag olamine, are used as the one or more reducing sugars acting as diluents in the extragranular composition of the inventive pharmaceutical tablet composition.
- the one or more reducing sugars are selected from the group consisting of lactose, maltose, glucose, arabinose and fructose, more preferably the one or more reducing sugar comprises or consists of lactose selected from the group consisting of lactose monohydrate, anhydrous lactose, spray dried lactose and co-processed lactose.
- lactose examples include Ludipress ® (lactose monohydrate 93 wt.%, 3.5 wt.% povidone (Kol- lidon ® 30) and 3.5 wt.% crospovidone (Kollidon ® CL); Cellactose ® (75% lactose and 25% micro- crystalline cellulose MCC); Starlac ® (85% lactose and 15% starch) and Combilac ® (70% lactose, 20% MCC and 10% corn starch).
- Ludipress ® lactose monohydrate 93 wt.%, 3.5 wt.% povidone (Kol- lidon ® 30) and 3.5 wt.% crospovidone (Kollidon ® CL)
- Cellactose ® (75% lactose and 25% micro- crystalline cellulose MCC
- Starlac ® 85% lactose and 15% starch
- Combilac ® 70% lactose, 20% MCC and 10% corn
- lactose as diluent in the tablet composition is advantageous, as lactose is in particular cheaper than other excipients and thus allows a more economic production of pharmaceutical eltrombopag olamine tablet compositions.
- lactose is advantageous, as a variety of commercially available grades (lactose monohydrate, anhydrous lactose and spray- dried lactose) exists, which enables the skilled person to choose the best fitting grade for the present situation. Accordingly, the skilled person is enabled with respect to all aspects of the present invention to select the best fitting lactose excipient based on the required characteristics for tablet compression.
- lactose excipient shall also facilitate non- sticking at the compression facilities
- lactose comprising a comparatively large particle size will be selected.
- fine grades are usually used for the wet granulation process, as they permit better mixing with other excipients.
- the reducing sugar content in the granular composition not comprising the eltrombopag olamine is preferably greater than 5 wt.%, more preferably at least 9 wt.%, even more preferably in the range of 15 to 75 wt.%, e.g., 20 to 25 wt.%, 30 to 35 wt.%, 36 to 39 wt.%, 40 to 44 wt.%, 45 to 51 wt.%, 52 to 57 wt.%, 58 to 65 wt.% or alternatively 70 to 75 wt.%, respectively based on the total weight of the pharmaceutical tablet composition.
- the inventive pharmaceutical eltrombopag olamine tablets is made using at least 33 to 38 wt.% lactose based on the total weight of the tablet.
- the inventive pharmaceutical eltrombopag tablet the relative content of lactose in comparison to the total weight of the tablet increases with reducing the relative content of the active ingredient eltrombopag olamine.
- an inventive tablet composition comprising 95.7 mg eltrombopag olamine (equivalent to 75 mg eltrombopag free acid) per tablet unit comprises, e.g.
- An inventive tablet composition comprising 63.8 mg eltrombopag olamine (equivalent to 50 mg eltrombopag free acid) per tablet unit comprises, e.g. 45 to 51 wt.%, preferably 47 wt.% lactose based on the total weight of the tablet.
- An inventive tablet composition comprising 31.9 mg eltrombopag olamine (equivalent to 25 mg eltrombopag free acid) per tablet unit comprises, e.g.
- An inventive tablet composition comprising 16 mg eltrombopag olamine (equivalent to 12.5 mg eltrombopag free acid) per tablet unit comprises, e.g. 58 to 65 wt.%, preferably 61 wt.% lactose based on the total weight of the tablet.
- the intragranular optional extragranular composition of the inventive pharmaceutical tablet composition further comprises or consists of one or more suitable binder agents, preferably one or more binder agents selected from the group consisting of povidone (non-crosslinked polyvinyl pyrrolidone, also called PVP, e.g. commercially available as Plasdone K29/32 or Kol- lidon® 30), copovidone (vinylpyrrolidone-vinyl acetate copolymer in a ratio of 3:2 by mass, also called PVPA A, e.g. commercially available as Kollidon® VA64), hydroxypropyl cellulose (also called HPC or hyprollose, e.g.
- povidone non-crosslinked polyvinyl pyrrolidone, also called PVP, e.g. commercially available as Plasdone K29/32 or Kol- lidon® 30
- copovidone vinylpyrrolidone-vinyl acetate copolymer in a ratio of 3:2
- low-substituted hydroxypropyl cellulose low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose (also called HPMC or hypromellose, e.g. com- shoutally available as MethocelTM K3 Premium LV), hydroxypropyl starch (also called HPS), polyethylene oxide, more preferably one or two binder agents are selected from povidone and copovidone.
- the low-substituted hydroxypropyl cellulose is preferably used based on its disintegrant properties.
- polyethylene oxide with molecular weight below 9000 g/mol which is usually named polyethylene glycol (also called PEG or Macrogol, e.g.
- polyvinyl alcohol e.g. commercially available as PVA Emprove ® 4-88
- polyvinyl caprolactam-polyvinyl acetate- polyethylene glycol graft copolymer e.g. commercially available as Soluplus ®
- polyethylene glycol-polyvinyl alcohol graft copolymer also called PEG-PVA, e.g. commercially available as Kollicoat ® IR
- sodium carboxymethyl cellulose also called Na-CMC, e.g. commercially available as WalocelTM CRT
- binder agents are in particular preferred in the intragranular composition.
- the amount of binder agent in the intragranular composition may be reduced (see also below paragraph).
- the additional use of one or more binder agents in the intragranular composition and optionally also in the extragranular composition is preferred, as the respective inventive tablet compositions show a reduced degradation of eltrombopag olamine at higher amounts of 9 wt.% or more, preferably 20 wt.% or more of reducing sugars, in particular lactose as set out in the example section.
- binder agents are generally classified as “semisynthetic polymeric binder agents” or “synthetic polymeric binder agents”.
- binder is defined as an agent used to increase the cohesion of the powdery particles or granules during the compression, in order to obtain pharmaceutical forms with a defined hardness, or to act as processing aid during the granulation process.
- the binder may be present in the pharmaceutical composition in the form of a single constituent / ingredient or in the form of a mixture of constituents / ingredients.
- the binder agents are classified into 3 classes: 1 ) “natural binder", 2) “semisynthetic polymeric binder", and 3) “synthetic polymeric binder”.
- the expression “semisynthetic polymeric binder” refers to a chemically modified natural polymer binder, usually a derivative of cellulose or starch, preferably selected from the group consisting of hydroxypropyl cellulose (HPC, hyprollose), hydroxy- propyl methyl cellulose (HPMC, hypromellose), sodium carboxymethyl cellulose, and hydroxy- propyl starch.
- HPC hydroxypropyl cellulose
- HPMC hypromellose
- sodium carboxymethyl cellulose sodium carboxymethyl cellulose
- hydroxy- propyl starch preferably selected from the group consisting of hydroxypropyl cellulose (HPC, hyprollose), hydroxy- propyl methyl cellulose (HPMC, hypromellose), sodium carboxymethyl cellulose, and hydroxy- propyl starch.
- ..synthetic polymeric binder refers to a fully chemically synthesized, human or machine made, non-natural polymer or co-polymer binder agent, preferably selected from the group consisting of povidone, copovidone, polyvinyl alcohol, polyethylene glycol (PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and polyethylene glycol-polyvinyl alcohol graft copolymer (PEG-PVA).
- polymeric binder / "polymer binder” refers to a group of polymeric binder agents consisting of "semisynthetic polymeric binders” and “synthetic polymeric binders”, as defined above.
- the inventive pharmaceutical tablet composition may further comprise suitable natural binder agents, preferably selected from the group consisting of starch or starch derivatives, e.g., corn starch, potato starch, pregelatinized starch, sodium starch; alginic acid or salts thereof, e.g. sodium alginate; gelatin, Guar gum; gum Arabic; Candelilla wax; and Carnauba wax.
- suitable natural binder agents preferably selected from the group consisting of starch or starch derivatives, e.g., corn starch, potato starch, pregelatinized starch, sodium starch; alginic acid or salts thereof, e.g. sodium alginate; gelatin, Guar gum; gum Arabic; Candelilla wax; and Carnauba wax.
- Starch and pregelatinized starch are multifunctional excipients. They can be considered as natural binders, but they can be used also as diluents, and furthermore also have disinte- grant-like properties.
- a disintegrant is typically an agent used in the preparation of solid pharmaceutical formulations which causes them to disintegrate and release their medicinal substances on contact with moisture. However, the disintegrant may also be considered as a diluent and/or binder, depending on the properties of the particular excipient employed as a disintegrant.
- a binder is typically a substance used to create a desired consistency in a formulation, whereby a diluent is typically considered as a bulking agent to increase the mass of the formulation.
- the disintegrant exhibits properties of disintegration upon contact with aqueous environments, and is preferably a non-soluble disintegrant, but may also show properties associated with a diluent or binder.
- PGS is a starch that has been chemically and/or mechanically processed to rupture all or part of the starch granules. This typically renders the starch flowable and directly compressible (Handbook of Pharmaceutical Excipients (Ed: Rowe)).
- Partially pregelatinized starch is commercially available.
- pregelatinized starch contains 5% of free amylose, 15% of free amylopectin, and 80% unmodified starch.
- Pregelatinized starch is typically obtained from maize (corn), potato, or rice starch.
- co-processed lactose is preferred, as it already comprises a mixture of lactose and one or more further excipients.
- the one or more further excipients in the co-processed lactose are preferable selected from microcrystalline cellulose (MCC), starch, povidone, and crospovidone (crosslinked polyvinyl pyrrolidone, so called PVPP or polyvinyl polypyrrolidone, e.g. commercial- ly available as Polyplasdone XL or Kollidon ® CL).
- co-processed lactose is available as, e.g., Ludipress ® which comprises of lactose, povidone (Kollidon ® 30) and cro- spovidone (Kollidon ® CL), Cellactose ® (lactose with MCC); Starlac ® (lactose with starch) and Combilac ® (lactose with MCC and starch).
- Ludipress ® which comprises of lactose, povidone (Kollidon ® 30) and cro- spovidone (Kollidon ® CL), Cellactose ® (lactose with MCC); Starlac ® (lactose with starch) and Combilac ® (lactose with MCC and starch).
- the intragranular and/or extragranular composition preferably the intragranular and extragranular composition further comprises suitable further diluent agents (in addition to the one or more reducing sugars), preferably one or more further diluent agents are selected from the group consisting of erythritol, isomalt, maltitol, xylitol, microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactitol, mannitol, sorbitol, maltodextrin more preferably one, two or more further diluent agents are selected from erythritol, isomalt, maltitol, xylitol, and microcrystalline cellulose, even more preferably the further diluent agents are selected from microcrystalline cellulose and one, two or more selected from erythritol, isomalt, maltitol and xylitol
- the inventive tablet composition comprises in addition to a reducing sugar in the respective granular composition, i.e. either the extra- or the intragranular composition one or more, preferably one additional diluent agent as set out above.
- a combination is in particular preferred for inventive tablet compositions with a low content of eltrombopag olamine, e.g. 16.05 mg, 32.1 mg, 64.2 mg.
- the composition comprising the eltrombopag olamine i.e. either the intra- or extragranular composition comprises one or more, preferably two further diluent agents as set out above, preferably comprising microcrystalline cellulose and one of the further diluent agents as set out above.
- the intragranular phase may reduce the disintegration time of the inventive tablet composition over storing time.
- a combination of diluent agents comprises one or more, preferably one soluble and one or more, preferably one insoluble diluent agent in the respective granular phases/compositions.
- Such a combination further facilitates the disintegration of the inventive tablet, in particular in case no further in particular intragranular disintegrant agent is used in the inventive tablet.
- Preferred examples of such an inventive combination comprise microcrystalline cellulose as insoluble diluent and lactose or xylitol as soluble diluents.
- the intragranular and/or extragranular composition preferably the extragranular composition further comprises suitable one or more disintegrant agents, preferably one or more disintegrant agents selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium, more preferably one or two selected from sodium starch glycolate, crospovidone and croscarmellose sodium.
- suitable one or more disintegrant agents preferably one or more disintegrant agents selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium, more preferably one or two selected from sodium starch glycolate, crospovidone and croscarmellose sodium.
- L-HPC low-substituted hydroxypropyl cellulose
- the disintegrant is applied in the extragranular composition.
- the inventive tablet composition comprises a higher amount of eltrombopag olamine in the intragranular phase and/or an insoluble diluent can be used in the intragranular phase in addition to eltrombopag olamine, then the same or different disintegrant agent may be used also in the intragranular composition, wherein the weight ratios of disintegrant in intra- and extragranular phase is preferably in the range of 1 :1 to 1 :5, in particular 1 :3 or 1 :4 or 1 :4.6.
- the intragranular phase may comprise no disintegrant agent and the extragranular phase may comprise sodium starch glycolate, crospovidone or croscarmellose sodium or a combination of sodium starch glycolate and crospovidone or sodium starch glycolate and croscarmellose sodium or crospovidone and croscarmellose sodium, more preferably sodium starch glycolate as disintegrant agent(s) or alternatively low-substituted hydroxypropyl cellulose as disintegrant, wherein the disintegrant agent in total in the extragranular phase is in particular present in a range of 5 to 10 wt.%, preferably 8 wt.% based on the total weight of the inventive tablet composition.
- the intragranular phase may comprise sodium starch glycolate, crospovidone or croscarmellose sodium or a combination of sodium starch glycolate and crospovidone or sodium starch glycolate and croscarmellose sodium or crospovidone and croscarmellose sodium, more preferably sodium starch glycolate as disintegrant agent(s) or alternatively low-substituted hydroxypropyl cellulose as disintegrant, wherein the disintegrant agent in total in the intragranular phase is in particular present in a weight range of 1 to 5 wt.%, preferably 2 wt.% based on the total weight of the inventive tablet composition, while the extragranular phase may comprise sodium starch glycolate, crospovidone or croscarmellose sodium, or a combination of sodium starch glycolate and crospovidone or sodium starch glycolate and croscarmellose sodium or crospovidone and croscarmellose sodium or alternatively low-substituted hydroxypropyl
- the extragranular composition of the inventive pharmaceutical tablet composition further comprises one or more suitable lubricant agents, preferably selected from the group consisting of magnesium stearate, stearic acid, and sodium stearyl fumarate, more preferably magnesium stearate.
- suitable lubricant agents preferably selected from the group consisting of magnesium stearate, stearic acid, and sodium stearyl fumarate, more preferably magnesium stearate.
- the pharmaceutical tablet composition is film coated with a coating agent, preferably comprising one or more pharmaceutically acceptable polymers, optionally one or more pharmaceutically acceptable plasticizers, and optionally one or more pharmaceutically acceptable pigments.
- the one or more polymer agents of the pharmaceutically acceptable coating agent are preferably selected from one or more of the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, polyvinyl alcohol, polyethylene glycol, polyethylene glycol-polyvinyl alcohol graft copolymer, and polysorbate.
- the one or more pigments are preferably selected from the group of titanium dioxide, aluminium lakes, and iron oxides, preferably iron oxide yellow, iron oxide red, and iron oxide black.
- inventive pharmaceutical tablet compositions comprising 16.05 mg or 32.1 mg eltrombopag olamine, or
- the total content of binder agent(s) is at least 0.5 wt.% or more, more preferably is in the range of 0.5 to 7 wt.%, more preferably 1 to 3 wt.% and/or ii.
- the total content of diluent agent(s) including the reducing sugar amount is at least 5 wt.% or more, preferably is present in the range of 10 to 86 wt.%, alternatively in the range of 15 to 80 wt.%, alternatively in the range of 7 to 62 wt.%, alternatively in the range of 63 wt.% to 86 wt.% and/or iii.
- the total content of the disintegrant agent(s) is at least 3 wt.% or more, preferably is in the range of 4 to 15 wt.%, more preferably 5 to 14 wt.%, even more preferably 6 to 12 wt.% or alternatively is in the range of 3 to 5 wt.% and/or iv.
- the total content of the lubricant agent(s) is at least 0.5 wt.% or more, preferably is present in the range of 0.5 to 5 wt.%, preferably 0.8 to 3 wt.%, more preferably 0.9 to 1.5 wt.% and more preferably is 1 wt.% and/or v.
- the total content of the coating agent(s) is at least 2 wt.%, preferably in the range of 3 to 7 wt.%, more preferably 4 to 5 wt.%, respectively based on the total weight of the pharmaceutical tablet composition.
- the intragranular composition comprises in addition to eltrombopag olamine at least one binder agent as set out above in an amount of at least 1 wt.% or more, more preferably in the range of 1 wt.% to 5 wt.%, more preferably in the range of 2 wt.% to 4 wt.% based on the total weight of the produced pharmaceutical tablet composition, more preferably the binder agent is povidone.
- the intragranular composition comprises one, two or more further diluent agents as set out above in a total amount of at least 10 wt.%, more preferably 19 to 22 wt.%, more preferably the further diluent agent is microcrystalline cellulose or a combination of microcrystalline cellulose and xylitol.
- the intragranular composition comprises one, two or more disintegrant agents as set out above in a total amount of at least 1 wt.%, more preferably 2 wt.%, more preferably the disintegrant agent is sodium starch glycolate or croscarmellose sodium, more preferably sodium starch glycolate.
- the extragranular composition comprises in addition to the reducing sugar content as diluent, one or more disintegrant agents, preferably in an amount of at least at least 3 wt.% or more, preferably 6 to 12 wt.%, more preferably the disintegrant agent is sodium starch glycolate or croscarmellose sodium or a mixture of sodium starch glycolate and croscarmellose sodium.
- the extragranular phase comprises one or more further binder agents, preferably in an amount of at least 0.5 wt.% or more, preferably 2 to 4 wt.%, more preferably povidone and optionally cro- spovidone.
- the extragranular composition comprises at least one lubricant, preferably in an amount of at least 0.5 wt.% or more, preferably 0.9 to 1 .2 wt.%, more preferably the lubri- cant is magnesium stearate.
- the inventive tablet composition is film coated comprising suitable coating agents, preferably in an amount of least 2 wt.%, preferably 3 to 5 wt.%. The respective weight amounts as set out before respectively are based on the total weight of the inventive tablet composition. According to a furthermore preferred embodiment, the total weight of the inventive tablet composition is 363 mg.
- the intragranular composition comprises the reducing sugar, preferably lactose, more preferably lactose monohydrate, and a binder agent, preferably polyvinyl pyrrolidone
- the extragranular composition comprises in addition to a therapeutically active amount of eltrombopag olamine a diluent agent, preferably microcrystalline cellulose, and optionally one or more of the following pharmaceutically acceptable excipient agents, such as a binder agent, preferably polyvinyl pyrrolidone, a disintegrants agent, preferably sodium starch glycolate and a lubrication agent, preferably magnesium stearate.
- the resulting inventive tablet composition is preferably film coated with a suitable coating as disclosed above.
- the inventive pharmaceutical tablet composition additionally comprises or consists of a therapeutically effective amount of one or more additional active ingredients.
- the one or more additional active ingredients may be comprised in the intragranular composition or - in case of prevention of interaction between the active ingredients and eltrombopag olamine - in composition not comprising the eltrombopag olamine.
- the one or more additional active ingredients are simultaneously or sequentially co-administered in a separate pharmaceutical formulation.
- the one or more additional active ingredients are selected from constituents which are effective in the treatment of prophylaxis of thrombocytopenia, preferably adult chronic immune (idiopathic) thrombocytopenic purpura (ITP), acquired severe aplastic anaemia (SAA) and/or chronic hepatitis C virus (HCV) infection.
- IDP adult chronic immune
- SAA acquired severe aplastic anaemia
- HCV chronic hepatitis C virus
- one or more additional active ingredients are selected from the group of corticosteroids, lithium carbonate, folate, rituximab, and immunoglobuline, in particular anti-Rh (D) immunoglobuline generally used to treat thrombocytopenia, in particular chronic immune (idiopathic) thrombocytopenic purpura (ITP).
- D anti-Rh
- ITP chronic immune thrombocytopenic purpura
- one or more additional active ingredients are selected from the group of anti-infective agents, such as antibiotics and antifungal agents, immunosuppressive agents, such as anti-thymocyte globulin (ATG) and cyclosporine-A (CSA) and cytokine agents, such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), generally used to treat acquired severe aplastic anaemia (SAA).
- anti-infective agents such as antibiotics and antifungal agents
- immunosuppressive agents such as anti-thymocyte globulin (ATG) and cyclosporine-A (CSA)
- cytokine agents such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), generally used to treat acquired severe aplastic anaemia (SAA).
- SAA severe aplastic anaemia
- one or more additional active ingredients are selected from the group of antiviral agents, such as daclatasvir, elbasvir, grazoprevir, ledipasvir, sofosbuvir, ombitasvir, paritaprevir, ritonavir, dasabuvir, simeprevir, sofosbuvir, velpatasvir, ribavirin, peginterferon alfa-2a or pegin- terferon alfa-2b generally used to treat chronic hepatitis C virus (HCV) infection.
- antiviral agents such as daclatasvir, elbasvir, grazoprevir, ledipasvir, sofosbuvir, ombitasvir, paritaprevir, ritonavir, dasabuvir, simeprevir, sofosbuvir, velpatasvir, ribavirin, peginterferon alfa-2a or pegin- terferon alfa-2b
- the properties or the physical and chemical stability of the inventive pharmaceutical tablet composition may be tested in conventional manner, e.g. by measurement of appearance, hardness (or resistance to crushing), disintegration time, dissolution, friability, water content, assay for eltrombopag olamine and/or its degradation products (related substances), and/or uniformity of dosage units or mass after storage at controlled storage conditions; e.g. at intermediate and/or accelerated conditions according to ICH guideline Q1 A(R2) (i.e. at 25 °C / 60 % relative humidity (RH) and/or at 40 °C / 75 % RH).
- ICH guideline Q1 A(R2) i.e. at 25 °C / 60 % relative humidity (RH) and/or at 40 °C / 75 % RH.
- the dissolution (profile) of the inventive pharmaceutical tablet composition according to the present invention e.g. a tablet or film-coated tablet, is stable over at least 6 months when stored preferably in Alu-Alu blisters at intermediate or long-term storage conditions, i.e. 25 °C / 60 % RH or 40 °C / 75 % RH.
- dissolution and further additional attributes such as, e.g., assay, related substances or uniformity of dosage units or mass are also stable after storage over at least 6 months when stored at intermediate or long-term storage conditions.
- stable in the context of the present invention means that a measured value falls within range of specified values determined in accordance with a respective applicable regulatory guideline, e.g. the European Pharmacopeia.
- the inventive pharmaceutical tablet composition may vary in shape and be, e.g., round, oval, oblong, cylindrical, caplet shaped or any other suitable shape, preferably it is round or caplet shaped.
- the inventive pharmaceutical tablet composition comprises means for dividing the tablet, such as scores or engravings.
- the inventive pharmaceutical tablet composition preferably film-coated tablet, has a diameter ranging between 3.5 and 15 mm and most preferably between 5.5 and 7.0 mm for round tablets and the dimension of a caplet is between 9.0 x 3.0 mm and 17.0 x 7.5 mm, preferably it is 12.7 x 5.9 mm. Thickness is ranging from 2.0 to 5.0 mm, preferably between 2.5 and 4.6 mm.
- the inventive pharmaceutical tablet composition has a suitable hardness (or resistance to crushing), preferably the film-coated tablets may have a hardness (or resistance to crushing) of at least 40 N, preferably from 50 N to 130 N, more preferably 85 N to 1 10 N.
- the inventive pharmaceutical tablet composition according to all aspects has a suitable disintegration time, preferably the film-coated tablets may have a disintegration time of at least 2 minutes, preferably in the range of 2 to 6 minutes.
- inventive pharmaceutical tablet composition preferably film-coated tablet
- inventive pharmaceutical tablet composition may be colored and/or marked so as to impart an individual appearance and to make them instantly recognizable.
- the use of dyes can serve to enhance the appearance as well as to identify the inventive pharmaceutical composition.
- Dyes suitable for use in pharmacy typically include carot- enoids, iron oxides or chlorophyll.
- the inventive pharmaceutical tablet composition, preferably a film-coated tablet may be marked using an imprint code.
- the inventive pharmaceutical composition may be packed in any conventional packaging known in the art, for example blisters, polypropylene or polyethylene (e.g. HDPE, high density polyethylene) containers or glass bottles.
- the inventive tablet composition is preferably packed in a blister known in the art, e.g. sealed aluminum blister (Alu-Alu), Aluminum / Aluminum peel-push blisters or PVC/PE/PVDC/aluminum-blisters.
- the inventive process of production of a pharmaceutical tablet comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars is characterized in that the process comprises or consists of the following steps: either a. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients, b. wet granulation of components mixed in step a) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, to form an intragranular composition, c.
- a suitable granulation fluid preferably water or an aqueous solution of a binder
- reducing sugars preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally further one or more pharmaceutically acceptable excipients to form an extragranular composition
- reducing sugars preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally further one or more pharmaceutically acceptable excipients
- step c) mixing the extragranular composition of step c) with the intragranular composition of step b) to form a tablet composition
- e. compressing the tablet composition of step d) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the intragranular phase and one or more reducing sugars in the extragranular phase, or f.
- reducing sugars preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally further one or more pharmaceutically acceptable excipients, g. wet granulation of components mixed in step f) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, to form an intragranular composition, h. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients to form an extragranular composition, i. mixing the extragranular composition of step h) with the intragranular composition of step g) to form a tablet composition, and j. compressing the tablet composition of step i) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the extragranular phase and one or more reducing sugars in the intragranular phase.
- a suitable granulation fluid preferably water or an aque
- the provided constituents such as eltrombopag olamine, reducing sugars, disinte- grants, binders, diluents and coating agents are sifted prior to use, preferably they are sifted through a # 35 mesh (Tyler Equivalent) screen, which corresponds to a screen with an opening of 0.420 mm in diameter.
- the provided constituents in step a) or in step f) are loaded into a high shear mixer granulator or an equivalent granulator and preferably mixed for 10, more preferably 5 minutes with impeller at preferably slow speed.
- the suitable granulation fluid preferably water or an aqueous solution of a binder, is added to the mixture of step a) or step f) in the high shear mixer granulator and the impeller is preferably used at low speed.
- the granules obtained in step c) or in step h) after wet granulation are subsequently dried at suitable conditions.
- step c) or in step h) preferably dried are subsequently milled, preferably using a Quadro ® Comil equipped with a suitable screen.
- step d) or step i the (milled) granules forming the intragranular phase and sifted and admixed extragranular constituents are loaded into a blender and mixed preferably for 10 minutes according to step d) or step i).
- this constituent is preferably subsequently added to the blender and mixed preferably for further 5 minutes in step d) or step i).
- step d) or step i) is compressed into the inventive pharmaceutical tablet composition preferably on a rotary tablet compression machine using suitable tooling and parameters in step e) or in step j).
- the resulting inventive pharmaceutical tablet composition of step e) or step j) is furthermore preferably film coated in a subsequent step using one or more pharmaceutically acceptable excipients as suitable coating agent.
- suitable coating agent comprises one or more polymers, optionally one or more plasticizers, and optionally one or more pigments.
- the preferred coating agents as disclosed with respect to the inventive pharmaceutical tablet composition can also be used with respect to the second aspect of the present invention.
- the amount of impurities measured for the inventive pharmaceutical tablet compositions of the first and third aspect initially after production is below detection limit (BLD).
- BLD detection limit
- the amount of impurities is still below detection limit for 40 % relative humidity (RH) and 50°C, 60°C and 70°C.
- RH relative humidity
- the impurities are detectable at a very low level for 50°C and an increased level for 75°C (see table 1 ).
- inventive pharmaceutical tablet compositions When using the regulatory accelerated stability assessment standards for Europe, the inventive pharmaceutical tablet compositions are sealed in Alu-Alu blisters and the amount of impurities is still below detection limit both after one or two months. Accordingly, the inventive pharmaceutical tablet compositions of the first and third aspect show a decreased degradation of eltrombopag olamine as active ingredient in comparison to the lactose composition of the prior art (see Kapsi declaration), where the composition already initially after production comprises 1 .5 % total impurities.
- the reduced degradation of eltrombopag olamine may be due to the use of the inventive combination of the lactose with polyvinyl pyrrolidone and/or may be due to the inventive production process according to which the eltrombopag olamine constituent is formulated with polyvinyl pyrrolidone in one composition and the lactose is added together with further polyvinyl pyrrolidone in the other composition.
- the inventive pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the composition comprising or consisting of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition or c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an intragranular composition and d) eltrombopag olamine in a therapeutically effective amount and one or
- the use the inventive pharmaceutical tablet composition is claimed, wherein the pharmaceutical tablet composition is used in the manufacture of a medicament for the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
- IDP immune thrombocytopenic purpura
- SAA acquired severe aplastic anaemia
- the method of treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA), comprises administering to a patient in need an inventive pharmaceutical tablet composition.
- the eltrombopag olamine constituent used in the following example formulations F1 to 38 exhibits polymorphic form I.
- Part A General Procedure for the wet granulation compression (eltrombopag olamine intragranular / lactose extragranular)
- step-1 Sifted materials of step-1 loaded into high shear mixer granulator and mixed for 5 minutes with impeller at slow speed.
- Step-2 material was granulated with a suitable binder solution, e.g., water or an aqueous solution such as aqueous povidone solution, at impeller slow speed.
- a suitable binder solution e.g., water or an aqueous solution such as aqueous povidone solution
- step-3 material The granules of step-3 material were dried in a suitable equipment to get required loss on drying.
- step-4 The dried granules of step-4 were milled using Quadro ® Comil equipped with suitable screen.
- step 7 Milled granules of step 5 and sifted extragranular materials of step 6 were loaded into the blender and mixed for 10 min.
- step 8 The blend mixture of step 8 was compressed into tablets on rotary tablet compression machine using suitable tooling and parameters.
- inventive pharmaceutical tablet compositions F1 -F37 are produced in accordance with the general procedure as set out in Part A above:
- Example F1 inventive pharmaceutical film-coated tablet composition
- inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
- Microcelac ® (Lactose monohydrate in an amount of 75 wt.
- microcrystalline cellulose 25 wt. % respectively 48.000
- Film-coated tablet weight (mg) 363.000
- Example F2 inventive pharmaceutical film-coated tablet composition
- Example F3 inventive pharmaceutical film-coated tablet composition
- lactose mono- hydrate microcrystalline cellulose
- microcrystalline cellulose polyvinyl pyrrolidone (povidone)
- polyvinyl pyrrolidone polyvinyl pyrrolidone
- crospovidone crosslinked insoluble polyvinylpyrrolidone
- sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
- Ludipress ® (Lactose monohydrate in an amount of 93 wt.
- Film-coated tablet weight (mg) 363.000
- Example F4 inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
- Example F5 inventive pharmaceutical film-coated tablet composition
- Example F6 inventive pharmaceutical film-coated tablet composition
- Example F7 inventive pharmaceutical film-coated tablet composition
- Film-coated tablet weight (mg) 363.000
- inventive pharmaceutical film-coated tablet compositions comprising co- processed lactose comprising lactose monohydrate, polyvinyl pyrrolidone (povidone) and cross- linked insoluble polyvinyl pyrrolidone (crospovidone), sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
- Film-coated tablet weight (mg) 363.000 363.000
- Examples F10 and F11 inventive pharmaceutical film-coated tablet compositions comprising lactose monohydrate, polyvinyl pyrrolidone (povidone), sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
- Film-coated tablet weight (mg) 363.000 363.000
- Example F12 inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose, xylitol and polyvinyl pyrroli- done (povidone) in intragranular phase
- Film-coated tablet weight (mg) 363.000
- Example F13 inventive pharmaceutical film-coated tablet composition
- inventive pharmaceutical film-coated tablet composition comprising anhydrous lactose, sodium starch glycolate and magnesium stearate in extragranular phase and eltrom- bopag olamine, microcrystalline cellulose, sodium starch glycolate and polyvinyl pyrrolidone (povidone) in intragranular phase
- Example F14 inventive pharmaceutical film-coated tablet composition
- Film-coated tablet weight (mg) 363.000
- Example F15 inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
- Example F16 inventive pharmaceutical film-coated tablet composition
- Examples F17 to F20 inventive pharmaceutical film-coated tablet composition
- lactose monohydrate polyvinyl pyrrolidone (povidone), sodium starch glycolate and magnesium stearate in extragranular phase and 16 mg, 31 .1 mg or 63.2 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg or 50 mg eltrombopag) in combination with microcrystalline cellulose and povidone in intragranular phase
- Stage-A (Dry Mix) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit)
- Film-coated tablet weight (mg) 363.000 363.000 363.000 363.000 363.000 363.000 363.000 363.000 363.000 Examples F21 and F22: inventive pharmaceutical film-coated tablet composition comprising Ludipress ® (93 wt.% lactose monohydrate, 3.5 wt.% polyvinyl pyrrolidone (Kollidon 30) and 3.5 wt.% crospovidone (Kollidon CL)) and sodium starch glycolate and magnesium stearate in ex- tragranular phase and 16 mg eltrombopag olamine (equivalent to 12.5 mg eltrombopag) in combination with microcrystalline cellulose and povidone in intragranular phase
- Stage-A (Dry Mix) (mg/unit) (mg/unit) (mg/unit)
- Film-coated tablet weight (mg) 363.000 181.500
- inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, copovidone, sodium starch glycolate and magnesium stearate in extra- granular phase and 16 mg eltrombopag olamine (equivalent to 12.5 mg eltrombopag) in combination with microcrystalline cellulose and copovidone in intragranular phase
- Stage-A (Dry Mix) (mg/unit) (mg/unit) (mg/unit)
- Film-coated tablet weight (mg) 363.000 181.500
- inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate and magnesium stearate in extragranular phase and 16 mg, 31 .9 mg, 63.2 mg or 95.7 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg, 50 mg or 75 mg eltrombopag) in combination with microcrystalline cellulose, polyvinyl pyrrolidone and sodium starch glycolate in intragranular phase
- Stage-A (Dry Mix) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit)
- Film-coated tablet weight (mg) 363.000 242.000 121.000 60.500
- Examples F29 to F32 inventive pharmaceutical film-coated tablet composition
- inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate and magnesium stearate in extragranular phase and 16 mg, 31.9 mg, or 63.2 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg, or 50 mg eltrombopag) in combination with microcrystalline cellulose, polyvinyl pyrrolidone (povidone) and sodium starch glycolate in intragranular phase
- Stage-A (Dry Mix) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit)
- Film-coated tablet weight (mg) 363.000 363.000 181.500
- Example F32 inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, mannitol, sodium starch glycolate and magnesium stearate in extragranular phase and 96.25 mg eltrombopag olamine (equivalent to 75 mg eltrombopag), microcrystalline cellulose, sodium starch glycolate, and polyvinyl pyrrolidone (povidone) in intragranular phase
- Stage-A (Dry Mix) (mg/unit)
- Example F33 inventive pharmaceutical film-coated tablet composition
- inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium and magnesium stearate in extragranular phase and 96.25 mg eltrombopag olamine (equivalent to 75 mg eltrombopag), microcrystalline cellulose, and polyvinyl pyrrolidone (povidone) in intragranular phase
- Stage-A (Dry Mix) (mg/unit)
- Examples F34 to F37 inventive pharmaceutical film-coated tablet composition
- inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stea- rate in extragranular phase and 16 mg, 31.9 mg, 63.2 mg or 95.7 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg, 50 mg or 75 mg eltrombopag) in combination with microcrystalline cellulose, polyvinyl pyrrolidone and sodium starch glycolate in intragranular phase
- Stage-A (Dry Mix) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit) (mg/unit)
- Part C General Procedure for the wet granulation compression (lactose intragranular / eltrombopag olamine extragranular)
- Stage A (Dry Mix / Wet Granulation)
- Stage-A materials were sifted through #35 mesh.
- step-1 Sifted materials of step-1 loaded into high shear mixer granulator and mixed for 5 minutes with impeller at slow speed.
- Step-2 material was granulated with a suitable binder solution, e.g., water or an aqueous solution such as aqueous povidone solution, at impeller slow speed.
- a suitable binder solution e.g., water or an aqueous solution such as aqueous povidone solution
- step-3 material The granules of step-3 material were dried in a suitable equipment to get required loss on drying.
- step-4 The dried granules of step-4 were milled using Quadro ® Comil equipped with suitable screen.
- step 7 Dried milled granules of step 5 and sifted extragranular materials of step 6 were loaded into the blender and mixed for 10 min.
- Lubrication material of Stage C e.g., magnesium stearate, was sifted through #35 mesh and added to blend mixture of step 7 and lubricated for 5 minutes.
- step 8 The blend mixture of step 8 was compressed into tablets on rotary tablet compression machine using suitable tooling and parameters.
- inventive pharmaceutical tablet composition F38 is produced in accordance with the general procedure as set out in Part C above:
- Example F38 inventive pharmaceutical film-coated tablet composition
- inventive pharmaceutical film-coated tablet composition comprising 96.25 mg eltrombopag olamine (equivalent to 75 mg eltrombopag), microcrystalline cellulose, polyvinyl pyrrolidone (povidone) and magnesium stearate in extragranular phase and lactose monohy- drate and polyvinyl pyrrolidone (povidone) in intragranular phase
- Stage-A (Dry Mix / Wet Granulation) (mg/unit)
- An Accelerated Stability Assessment Program for up to 2-3 weeks under open exposure, according to Waterman 201 1 (Waterman KC, The application of the Accelerated Stability Assessment Program (ASAP) to quality by design (QbD) for drug product stability, AAPS PharmSciTech, Vol. 12, No. 3, September 2011) is usually applied for a quick estimation of chemical stability (cf. Table 1 ).
- a precise relative comparison of stability of two different compositions, or more precise shelf-life prediction compared with long-term and accelerated stability in commercial blister packaging can be conducted according to ICH guideline Q1A(R2) (cf. Table 2).
- the amount of impurities measured for the inventive pharmaceutical tablet compositions initially after production are below detection limit (BDL).
- BDL detection limit
- inventive eltrombopag olamine tablets packaged preferably in Alu-Alu blister will show less impurities at real time storage condition, as the water vapor transmission rate (WVTR) for Alu-Alu blister is reduced to the minimum.
- WVTR water vapor transmission rate
- Table 2 shows the accelerated stability testings shown in table 2 below. Accordingly, for tablets packaged in the commercially representative packaging material under accelerated storage conditions, which are also used in the Kapsi declaration, the degradation of eltrombopag olamine as active ingredient in the inventive pharmaceutical tablet compositions is decreased in comparison to the lactose containing tablet composition of the prior art (see Kapsi declaration), where the tablet composition already initially after production comprises 1.5 % total impurities.
- the physical and chemical stability of the inventive pharmaceutical tablet composition may be tested in conventional manner, in particular at accelerated conditions according to ICH guideline Q1A(R2) (i.e. at 25 °C / 60 % relative humidity (RH) and/or at 40 °C / 75 % RH).
- ICH guideline Q1A(R2) i.e. at 25 °C / 60 % relative humidity (RH) and/or at 40 °C / 75 % RH.
- the accelerated stability tests as set out in table 2 above have been performed according to applicable pharmaceutical regulatory standards as described e.g. in ICH or EMA guidelines and/or the European Pharmacopeia (EP), wherein the inventive pharmaceutical tablet composition have been packed in Alu-Alu blisters.
- EP European Pharmacopeia
- inventive pharmaceutical tablet compositions show no degradation within six month accelerated storage.
- the fact that no degradation products of eltrombopag olamine could be detected may be due to the separation of eltrombopag olamine in the intragranular phase and the reducing sugar, preferably lactose in the extragranular phase.
- the additional use of a polymeric binder agent, in particular povidone, in the intragranular phase and/or extragranular phase, in particular the extragranular phase and optionally the intragranular phase seems to be advantageous to further facilitate the decreased degradation of eltrombopag olamine in the inventive tablet composition.
- Dissolution testing according to tables 3-7 was performed using USP Apparatus II, 50 rpm, 900 ml of phosphate buffer pH 6.8 containing 0.5% Tween 80 as recommended for Eltrombopag Olamine in the FDA Dissolution Methods Database on the FDA webpage. Based on the Ph. Eur. (5.17.1 ) recommendation for immediate-release dosage forms, the specification is set as at least 75% of the active substance is dissolved within 45 minutes.
- the experimental data of table 3 shows that 75 wt.% or more, preferably more than 80 wt.%, more preferably more than 90 wt.% of eltrombopag olamine of the inventive pharmaceutical tablet compositions is dissolved within 45 minutes in accordance with the regulatory standard test.
- inventive eltrombopag tablet compositions F9 and F1 1 the test results could be confirmed after 1 month storage in Alu-Alu blister under accelerated condition at 40°C and 75 % relative humidity.
- inventive eltrombopag tablet composition F1 1 the test results could be confirmed also after 6 months storage in Alu-Alu blister under accelerated condition at 40°C and 75 % relative humidity.
- inventive tablet compositions are not only stable over preferably 6 month, they also comply with the regulatory standards for dissolution testings, where at least 75 wt.% of eltrombopag olamine needs to be dissolved within 45 minutes.
- dissolution testings concerning, e.g. F17, F18, F20, F21 , F23, and F25-F38, show that after 45 minutes at least 75 wt.%, preferably between 86 and 100 wt.% eltrombopag olamine based on the total weight of the eltrombopag olamine content in the tablet is dissolved.
- inventive eltrombopag tablet composition F34 the test results could be confirmed after 1 month storage in Alu-Alu blister under accelerated condition at 40°C and 75 % relative humidity.
- inventive eltrombopag tablet composition F38 the test results could be confirmed after 14 days storage under open exposure stress condition at 50°C and 75 % relative humidity.
- the dissolution of the inventive formulations of the present invention is comparable to the commercially available reference product Revolade ® film-coated tablets (FCTs), as shown below in tables 4, 5, 6, and 7 for the 75 mg, 50 mg, 25 mg, and 12.5 mg strength, correspondingly.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical tablet composition comprisingeltrombopag olamine and one or more reducing sugars, a production process therefore, a pharmaceutical tablet composition comprising eltrombopag olamine and one or more reducing sugars obtainable by the production process, a use / method of use of the pharmaceutical tablet compositions in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP),thrombocytopenia and/or acquired severe aplastic anaemia(SAA).
Description
Pharmaceutical Tablet Composition comprising Eltrombopag Olamine
Technical Field:
The present invention relates to a pharmaceutical tablet composition comprising eltrombopag olamine and one or more reducing sugars, a production process therefore, a pharmaceutical tablet composition comprising eltrombopag olamine and one or more reducing sugars obtainable by the production process, a use / method of use of the pharmaceutical tablet compositions in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
Background of the invention:
3'-(N'-[1 -(3,4-dimethylphenyl)-3-methyl-5-oxo-1 ,5-dihydropyrazol-4-ylidene]hydrazino}-2'- hydroxy-biphenyl-3-carboxylic acid - 2-aminoethanol (1 :2) (hereinafter and in the context of the present invention called eltrombopag olamine, CAS 496775-62-3) is a non-peptide haematopoietic receptor agonist, which mimics haematopoietic growth factors, including thrombopoietin (TPO), particularly enhancing platelet production and, thus, is particularly useful in the treatment of thrombocytopenia (see e.g. WO 03/098992 A2 and WO 2008/136843A1 ).
In Europe eltrombopag olamine is approved under the tradename Revolade® comprising eltrombopag olamine in an amount corresponding to 12.5 mg, 25 mg, 50 mg, and 75 mg eltrombopag free acid in tablet form. In USA eltrombopag olamine is approved under the tradename Promacta® comprising eltrombopag olamine in an amount corresponding to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg eltrombopag free acid in tablet form. Revolade® tablets are packed in Alu-Alu blisters, whereas Promacta® tablets are packed in HDPE bottles.
In Europe, Revolade® is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Revolade® may be considered as second line treatment for adult non- splenectomised patients where surgery is contraindicated.
Revolade® is also indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
Revolade® is furthermore indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
In WO 03/098992 A2 an eltrombopag tablet composition is disclosed in example 6 which comprises in addition to 8.45 mg eltrombopag olamine, furthermore 1 12 mg microcrystalline cellulose, 70 mg lactose, 8 mg sodium starch glycolate and 2 mg magnesium stearate.
It is, however, known, that eltrombopag olamine undergoes a Maillard reaction with respective pharmaceutically acceptable excipients, such as reducing sugars, e.g. lactose. It is known that eltrombopag olamine is degraded in presence of lactose and forms impurities, which can be measured in the pharmaceutical tablet composition. Mr. Kapsi, one of the inventors of WO 2008/136843 A1 provided in the corresponding US examination of US 2010/0040684 A1 a declaration (in the context of the present application called "Kapsi declaration") disclosing experimental stability data for the use of the lactose containing eltrombopag tablet composition of example 6 in WO 03/098992 A2 in comparison to a tablet formulation, which is free of reducing sugars using mannitol instead.
According to the Kapsi declaration, the eltrombopag olamine tablet formulation comprising lactose shows an "increase in degradation products when compared to the mannitol based formulation (4 fold difference in degradation products at 3 months" (see section Results on page 1 ). In section 5 on page 5 of the Kapsi declaration Mr. Kapsi followed that the "experimental data described herein demonstrates that the formulation described as Example 6 in publication WO 03/098992 A2 leads to a tablet formulation with a four-fold higher level of degradation products at 3 months and in my experience leads to an unacceptable tablet formulation".
In order to avoid unacceptable degradation of eltrombopag olamine, WO 2008/136843 A1 teaches to use diluents substantially free of reducing sugars, in particular using mannitol. The avoidance of reducing sugars as pharmaceutical excipient in an eltrombopag olamine pharmaceutical tablet is continued in WO 2012/121957 A1 and WO 2015/0121957 A2.
It would, however, be desirable to provide an alternative solution for a stable eltrombopag olamine pharmaceutical tablet composition, wherein the degradation level of eltrombopag olamine is negligible and the pharmaceutical tablet composition fulfills the regulatory stability criteria for pharmaceutical tablets. Furthermore, it would be desirable that the pharmaceutical tablet composition is more economic in costs per unit and/or allows tuning one or more pharmaceutical technological aspects during the production process.
Brief description of the invention:
One or more problems of the present invention is/are solved by the subjects of the independent claims. Advantages (preferred embodiments) are set out in the detailed description hereinafter as well as in the dependent claims.
Accordingly, a first aspect of the present invention relates to a pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the composition comprises or consists of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition or c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an intragranular composition and d) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an extragranular composition.
A second aspect of the present invention relates to an inventive pharmaceutical tablet composition for use in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
A third aspect of the present invention relates to a process of production of an inventive pharmaceutical tablet comprising eltrombopag olamine as active ingredient and one or more pharma-
ceutically acceptable excipients including one or more reducing sugars, characterized in that the process comprises the following steps: either a. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients, b. wet granulation of components mixed in step a) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, in a suitable amount to form an intragranular composition, c. mixing one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients to form an extragranular composition, d. mixing the extragranular composition of step c) with the intragranular composition of step b) to form a tablet composition, and e. compressing the tablet composition of step d) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the intragranular phase and one or more reducing sugars in the extragranular phase, or f. mixing one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally further one or more pharmaceutically acceptable excipients, g. wet granulation of components mixed in step f) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, to form an intragranular composition, h. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients to form an extragranular composition, i. mixing the extragranular composition of step h) with the intragranular composition of step g) to form a tablet composition, and j. compressing the tablet composition of step i) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the extragranular phase and one or more reducing sugars in the intragranular phase.
A fourth aspect of the present invention relates to a pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the composition which comprises or consists of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition, or c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an intragranular composition and d) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an extragranular composition is obtainable by the inventive production process.
A fifth aspect of the present invention relates to a use of an inventive pharmaceutical tablet composition, wherein the pharmaceutical tablet composition is used in the manufacture of a medicament for the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
A sixth aspect of the present invention relates to a method of treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA), comprising administering to a patient in need an inventive pharmaceutical tablet composition.
The inventive aspects of the present invention as disclosed hereinbefore can comprise - in case it is reasonable for a person skilled in the art - any possible combination of the preferred inventive embodiments as set out in the dependent claims or disclosed in the following detailed description.
Detailed description of the invention:
It has surprisingly been found by the present inventors, that the inventive pharmaceutical tablet comprising eltrombopag olamine in one granular composition (either intra- or extragranular) and one or more reducing sugars in a different granular composition (either extra- or intragranular) is not subjected to a substantial degradation of the active ingredient eltrombopag olamine in view of Maillard reactions with the reducing sugar and, thus, fulfills the regulatory stability requirements for commercializing the pharmaceutical eltrombopag olamine tablet (see example section Part E, tables 1 and 2). According to a preferred embodiment of the present invention, the inventive pharmaceutical tablet is stable over at least 6 months when stored preferably in Alu-Alu blisters at intermediate or long-term storage conditions, preferably at 25°C / 60% relative humidity (RH) and/or 40°C / 75 % RH. The inventive pharmaceutical tablet composition according to all aspects of the present invention comprises reducing sugars only in that granular composition (phase), which does not comprise the eltrombopag olamine constituent. Thus, in case eltrombopag olamine is present in the intragranular composition, the reducing sugar is present in the extragranular composition and in case the eltrombopag olamine is present in the extragranular composition, the reducing sugar is present in the intragranular composition.
Furthermore, the experimental data provided in table 3 in Part E) of the example section shows that 75 wt.% or more, preferably more than 80 wt.%, more preferably more than 90 wt.% of eltrombopag olamine in the inventive pharmaceutical tablet composition is dissolved within 45 minutes in accordance with the regulatory standard test.
The finding of the present inventors is moreover surprising, as it has been disclosed in the so called Kapsi declaration that eltrombopag olamine compositions comprising lactose are subject to severe degradation and, thus, do not fulfill the stability requirements for commercializing the respective pharmaceutical eltrombopag olamine tablet. The originator accordingly exchanged the lactose excipient by a non-reducing sugar, namely mannitol to fulfill the stability requirements.
Thus, by use of the inventive teaching, namely by separating the eltrombopag olamine active ingredient and the reducing sugar in different granular compositions, it is possible to maintain the use of a reducing sugar as diluent constituent in the tablet formulation of eltrombopag olamine and at the same time achieve a suitable dissolution profile for the inventive pharmaceutical tablet composition.
In the context of the present invention the term "intragranular composition" refers to tablet constituents which are wet granulated and thus forming granules to be further processed as intragranular composition / phase of the inventive pharmaceutical tablet composition. In case the
intragranular tablet constituents comprise a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients, then the intragranular composition does not comprise a reducing sugar, e.g. lactose, as pharmaceutically acceptable excipi- ent. Alternatively, in case the intragranular composition comprises a reducing sugar, e.g. lactose and optionally one or more pharmaceutically acceptable excipients, then the intragranular composition does not comprise eltrombopag olamine.
The "extragranular composition" is admixed with the granules of the intragranular composition and the mixture forms the basis for the tablet composition. This mixture is subsequently compressed to form the inventive pharmaceutical tablet composition. In case the extragranular composition comprises or consists of one or more reducing sugars and optionally one or more further pharmaceutical excipients then the extragranular composition does not comprise eltrombopag olamine. Alternatively, in case the extragranular composition comprises eltrombopag olamine and optionally one or more pharmaceutically acceptable excipients, then the extragranular composition does not comprise a reducing sugar, in particular lactose.
In the context with all inventive aspects of the present invention, the inventive pharmaceutical tablet composition comprises eltrombopag olamine as the active ingredient in a therapeutically effective amount and optionally one or more further active ingredients. In the context of all aspects and preferred embodiments of the present invention, the term "eltrombopag olamine" refers to an amorphous form or one or more polymorphic crystalline forms of eltrombopag olamine, wherein eltrombopag olamine has been defined hereinbefore as eltrombopag biseth- anolamine. The amorphous as well as polymorphic forms I, II, and III of eltrombopag olamine have been disclosed, e.g., in WO 2010/1 14943 A1 . More preferably, eltrombopag olamine in particular polymorphic form I of eltrombopag olamine (cf. figure 28 of WO 2010/1 14943 A1 shows polymorphic form I of eltrombopag bisethanolamine) is used in accordance with all aspects and preferred embodiments of the present invention. Furthermore, the eltrombopag olamine is generally used exhibiting suitable particle sizes for formulating the inventive pharmaceutical tablet composition, wherein preferably the particle size distribution by volume (PSD) is 30 m or less for 90 Vol. % of the particles (D 0.9), 8 m or less for 50 Vol. % of the particles (D 0.5), and/or 2 μηη or less for 10 Vol. % of the particles (D 0.1 ). The particle size distribution by volume may be determined by use of the Malvern technique (by volume). In preferred embodiments of all aspects of the present invention, the active ingredient eltrombopag olamine is used per tablet unit in an amount of 16.05 mg, 32.1 mg, 64.2 mg, 96.3 mg or 128.4 mg eltrombopag olamine (respectively corresponding to 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg eltrombopag free acid).
In view of eltrombopag olamine as active ingredient, the inventive pharmaceutical tablet composition is effective for use in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
Preferably the inventive pharmaceutical tablet composition is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) in splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). The inventive pharmaceutical tablet composition may also be considered as second line treatment for adult non-splenectomised patients where surgery is contraindicated.
The inventive pharmaceutical tablet composition is preferably furthermore indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
The inventive pharmaceutical tablet composition is preferably furthermore indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
According to all aspects of the present invention suitable reducing sugars, i.e. sugar constituents which generally may form a Maillard reaction with the active ingredient eltrombopag olamine, are used as the one or more reducing sugars acting as diluents in the extragranular composition of the inventive pharmaceutical tablet composition. In an alternative or cumulative preferred embodiment of the present invention the one or more reducing sugars are selected from the group consisting of lactose, maltose, glucose, arabinose and fructose, more preferably the one or more reducing sugar comprises or consists of lactose selected from the group consisting of lactose monohydrate, anhydrous lactose, spray dried lactose and co-processed lactose. Examples of co-processed lactose are Ludipress® (lactose monohydrate 93 wt.%, 3.5 wt.% povidone (Kol- lidon®30) and 3.5 wt.% crospovidone (Kollidon® CL); Cellactose® (75% lactose and 25% micro- crystalline cellulose MCC); Starlac® (85% lactose and 15% starch) and Combilac® (70% lactose, 20% MCC and 10% corn starch).
The use of lactose as diluent in the tablet composition is advantageous, as lactose is in particular cheaper than other excipients and thus allows a more economic production of pharmaceutical eltrombopag olamine tablet compositions. Furthermore the use of lactose is advantageous, as a variety of commercially available grades (lactose monohydrate, anhydrous lactose and spray- dried lactose) exists, which enables the skilled person to choose the best fitting grade for the present situation. Accordingly, the skilled person is enabled with respect to all aspects of the
present invention to select the best fitting lactose excipient based on the required characteristics for tablet compression. For example, in case the lactose excipient shall also facilitate non- sticking at the compression facilities, lactose comprising a comparatively large particle size will be selected. In case lactose monohydrate is used, fine grades are usually used for the wet granulation process, as they permit better mixing with other excipients.
In accordance with the present invention, the reducing sugar content in the granular composition not comprising the eltrombopag olamine, thus, either the extra- or intragranular composition of the inventive pharmaceutical tablet composition is preferably greater than 5 wt.%, more preferably at least 9 wt.%, even more preferably in the range of 15 to 75 wt.%, e.g., 20 to 25 wt.%, 30 to 35 wt.%, 36 to 39 wt.%, 40 to 44 wt.%, 45 to 51 wt.%, 52 to 57 wt.%, 58 to 65 wt.% or alternatively 70 to 75 wt.%, respectively based on the total weight of the pharmaceutical tablet composition. According to an alternative embodiment of the present invention, the inventive pharmaceutical eltrombopag olamine tablets is made using at least 33 to 38 wt.% lactose based on the total weight of the tablet. According to a preferred embodiment the inventive pharmaceutical eltrombopag tablet, the relative content of lactose in comparison to the total weight of the tablet increases with reducing the relative content of the active ingredient eltrombopag olamine. Accordingly, an inventive tablet composition comprising 95.7 mg eltrombopag olamine (equivalent to 75 mg eltrombopag free acid) per tablet unit comprises, e.g. 33 to 38 wt.%, preferably 35 wt.% lactose based on the total weight of the tablet. An inventive tablet composition comprising 63.8 mg eltrombopag olamine (equivalent to 50 mg eltrombopag free acid) per tablet unit comprises, e.g. 45 to 51 wt.%, preferably 47 wt.% lactose based on the total weight of the tablet. An inventive tablet composition comprising 31.9 mg eltrombopag olamine (equivalent to 25 mg eltrombopag free acid) per tablet unit comprises, e.g. 55 to 62 wt.%, preferably 59 wt.% lactose based on the total weight of the tablet. An inventive tablet composition comprising 16 mg eltrombopag olamine (equivalent to 12.5 mg eltrombopag free acid) per tablet unit comprises, e.g. 58 to 65 wt.%, preferably 61 wt.% lactose based on the total weight of the tablet.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention, the intragranular optional extragranular composition of the inventive pharmaceutical tablet composition further comprises or consists of one or more suitable binder agents, preferably one or more binder agents selected from the group consisting of povidone (non-crosslinked polyvinyl pyrrolidone, also called PVP, e.g. commercially available as Plasdone K29/32 or Kol- lidon® 30), copovidone (vinylpyrrolidone-vinyl acetate copolymer in a ratio of 3:2 by mass, also called PVPA A, e.g. commercially available as Kollidon® VA64), hydroxypropyl cellulose (also called HPC or hyprollose, e.g. commercially available as Klucel™ ELF), low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose (also called HPMC or hypromellose, e.g. com-
mercially available as Methocel™ K3 Premium LV), hydroxypropyl starch (also called HPS), polyethylene oxide, more preferably one or two binder agents are selected from povidone and copovidone. According to a preferred embodiment, the low-substituted hydroxypropyl cellulose is preferably used based on its disintegrant properties. Furthermore it is preferred to use polyethylene oxide with molecular weight below 9000 g/mol, which is usually named polyethylene glycol (also called PEG or Macrogol, e.g. commercially available as Carbowax™ PEG). Alternatively or cumulatively preferred are one or more constituents of the group consisting of polyvinyl alcohol (e.g. commercially available as PVA Emprove® 4-88), , polyvinyl caprolactam-polyvinyl acetate- polyethylene glycol graft copolymer (e.g. commercially available as Soluplus®), polyethylene glycol-polyvinyl alcohol graft copolymer (also called PEG-PVA, e.g. commercially available as Kollicoat® IR), and sodium carboxymethyl cellulose (also called Na-CMC, e.g. commercially available as Walocel™ CRT). The use of one or more binder agents is in particular preferred in the intragranular composition. In case co-processed lactose comprising binder agents are used in the extragranular phase, then the amount of binder agent in the intragranular composition may be reduced (see also below paragraph). The additional use of one or more binder agents in the intragranular composition and optionally also in the extragranular composition is preferred, as the respective inventive tablet compositions show a reduced degradation of eltrombopag olamine at higher amounts of 9 wt.% or more, preferably 20 wt.% or more of reducing sugars, in particular lactose as set out in the example section.
The above mentioned suitable binder agents are generally classified as "semisynthetic polymeric binder agents" or "synthetic polymeric binder agents".
In the context of the present invention the term "binder" is defined as an agent used to increase the cohesion of the powdery particles or granules during the compression, in order to obtain pharmaceutical forms with a defined hardness, or to act as processing aid during the granulation process. The binder may be present in the pharmaceutical composition in the form of a single constituent / ingredient or in the form of a mixture of constituents / ingredients. In the context of the present invention the binder agents are classified into 3 classes: 1 ) "natural binder", 2) "semisynthetic polymeric binder", and 3) "synthetic polymeric binder".
In the context of the present invention the expression "semisynthetic polymeric binder" refers to a chemically modified natural polymer binder, usually a derivative of cellulose or starch, preferably selected from the group consisting of hydroxypropyl cellulose (HPC, hyprollose), hydroxy- propyl methyl cellulose (HPMC, hypromellose), sodium carboxymethyl cellulose, and hydroxy- propyl starch.
In the context of the present invention the expression ..synthetic polymeric binder" refers to a fully chemically synthesized, human or machine made, non-natural polymer or co-polymer binder agent, preferably selected from the group consisting of povidone, copovidone, polyvinyl alcohol, polyethylene glycol (PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and polyethylene glycol-polyvinyl alcohol graft copolymer (PEG-PVA).
In the context of the present invention the expression "polymeric binder" / "polymer binder" refers to a group of polymeric binder agents consisting of "semisynthetic polymeric binders" and "synthetic polymeric binders", as defined above.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention, the inventive pharmaceutical tablet composition may further comprise suitable natural binder agents, preferably selected from the group consisting of starch or starch derivatives, e.g., corn starch, potato starch, pregelatinized starch, sodium starch; alginic acid or salts thereof, e.g. sodium alginate; gelatin, Guar gum; gum Arabic; Candelilla wax; and Carnauba wax.
Starch and pregelatinized starch (PGS) are multifunctional excipients. They can be considered as natural binders, but they can be used also as diluents, and furthermore also have disinte- grant-like properties. A disintegrant is typically an agent used in the preparation of solid pharmaceutical formulations which causes them to disintegrate and release their medicinal substances on contact with moisture. However, the disintegrant may also be considered as a diluent and/or binder, depending on the properties of the particular excipient employed as a disintegrant. A binder is typically a substance used to create a desired consistency in a formulation, whereby a diluent is typically considered as a bulking agent to increase the mass of the formulation. Accordingly, the disintegrant exhibits properties of disintegration upon contact with aqueous environments, and is preferably a non-soluble disintegrant, but may also show properties associated with a diluent or binder. PGS is a starch that has been chemically and/or mechanically processed to rupture all or part of the starch granules. This typically renders the starch flowable and directly compressible (Handbook of Pharmaceutical Excipients (Ed: Rowe)). Partially pregelatinized starch is commercially available. In some embodiments, pregelatinized starch contains 5% of free amylose, 15% of free amylopectin, and 80% unmodified starch. Pregelatinized starch is typically obtained from maize (corn), potato, or rice starch.
According to an alternative or cumulative preferred embodiment of the present invention, the use of co-processed lactose is preferred, as it already comprises a mixture of lactose and one or more further excipients. The one or more further excipients in the co-processed lactose are preferable selected from microcrystalline cellulose (MCC), starch, povidone, and crospovidone (crosslinked polyvinyl pyrrolidone, so called PVPP or polyvinyl polypyrrolidone, e.g. commercial-
ly available as Polyplasdone XL or Kollidon® CL). Commercially available co-processed lactose is available as, e.g., Ludipress® which comprises of lactose, povidone (Kollidon® 30) and cro- spovidone (Kollidon® CL), Cellactose® (lactose with MCC); Starlac® (lactose with starch) and Combilac® (lactose with MCC and starch). In case the further excipients of the co-processed lactose is also present as separate excipient in a different granular phase, then the amount of the separate excipient of the other granular phase may be reduced.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention, the intragranular and/or extragranular composition, preferably the intragranular and extragranular composition further comprises suitable further diluent agents (in addition to the one or more reducing sugars), preferably one or more further diluent agents are selected from the group consisting of erythritol, isomalt, maltitol, xylitol, microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactitol, mannitol, sorbitol, maltodextrin more preferably one, two or more further diluent agents are selected from erythritol, isomalt, maltitol, xylitol, and microcrystalline cellulose, even more preferably the further diluent agents are selected from microcrystalline cellulose and one, two or more selected from erythritol, isomalt, maltitol and xylitol, preferably xylitol.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention, the inventive tablet composition comprises in addition to a reducing sugar in the respective granular composition, i.e. either the extra- or the intragranular composition one or more, preferably one additional diluent agent as set out above. Such a combination is in particular preferred for inventive tablet compositions with a low content of eltrombopag olamine, e.g. 16.05 mg, 32.1 mg, 64.2 mg.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention it may be preferred that the composition comprising the eltrombopag olamine, i.e. either the intra- or extragranular composition comprises one or more, preferably two further diluent agents as set out above, preferably comprising microcrystalline cellulose and one of the further diluent agents as set out above. Such a combination is preferred as the use of microcrystalline cellulose alone as diluent agent in the respective phase, preferably the intragranular phase may reduce the disintegration time of the inventive tablet composition over storing time.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention it may be preferred that a combination of diluent agents comprises one or more, preferably one soluble and one or more, preferably one insoluble diluent agent in the respective granular phases/compositions. Such a combination further facilitates the disintegration of the inventive tablet, in particular in case no further in particular intragranular disintegrant agent is
used in the inventive tablet. Preferred examples of such an inventive combination comprise microcrystalline cellulose as insoluble diluent and lactose or xylitol as soluble diluents.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention, the intragranular and/or extragranular composition, preferably the extragranular composition further comprises suitable one or more disintegrant agents, preferably one or more disintegrant agents selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium, more preferably one or two selected from sodium starch glycolate, crospovidone and croscarmellose sodium. Alternatively, low-substituted hydroxypropyl cellulose (L-HPC) is used as disintegrant agent. Generally the disintegrant is applied in the extragranular composition. In case, however, the inventive tablet composition comprises a higher amount of eltrombopag olamine in the intragranular phase and/or an insoluble diluent can be used in the intragranular phase in addition to eltrombopag olamine, then the same or different disintegrant agent may be used also in the intragranular composition, wherein the weight ratios of disintegrant in intra- and extragranular phase is preferably in the range of 1 :1 to 1 :5, in particular 1 :3 or 1 :4 or 1 :4.6.
As an example, the intragranular phase may comprise no disintegrant agent and the extragranular phase may comprise sodium starch glycolate, crospovidone or croscarmellose sodium or a combination of sodium starch glycolate and crospovidone or sodium starch glycolate and croscarmellose sodium or crospovidone and croscarmellose sodium, more preferably sodium starch glycolate as disintegrant agent(s) or alternatively low-substituted hydroxypropyl cellulose as disintegrant, wherein the disintegrant agent in total in the extragranular phase is in particular present in a range of 5 to 10 wt.%, preferably 8 wt.% based on the total weight of the inventive tablet composition.
As an alternative example, the intragranular phase may comprise sodium starch glycolate, crospovidone or croscarmellose sodium or a combination of sodium starch glycolate and crospovidone or sodium starch glycolate and croscarmellose sodium or crospovidone and croscarmellose sodium, more preferably sodium starch glycolate as disintegrant agent(s) or alternatively low-substituted hydroxypropyl cellulose as disintegrant, wherein the disintegrant agent in total in the intragranular phase is in particular present in a weight range of 1 to 5 wt.%, preferably 2 wt.% based on the total weight of the inventive tablet composition, while the extragranular phase may comprise sodium starch glycolate, crospovidone or croscarmellose sodium, or a combination of sodium starch glycolate and crospovidone or sodium starch glycolate and croscarmellose sodium or crospovidone and croscarmellose sodium or alternatively low-substituted hydroxypropyl cellulose, wherein the disintegrant agent in total in the extragranular phase is in particular
present in a range of 5 to 10 wt.%, preferably 8 wt.% based on the total weight of the inventive tablet composition.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention, the extragranular composition of the inventive pharmaceutical tablet composition further comprises one or more suitable lubricant agents, preferably selected from the group consisting of magnesium stearate, stearic acid, and sodium stearyl fumarate, more preferably magnesium stearate.
According to a further alternative or cumulative preferred embodiment of all aspects of the present invention the pharmaceutical tablet composition is film coated with a coating agent, preferably comprising one or more pharmaceutically acceptable polymers, optionally one or more pharmaceutically acceptable plasticizers, and optionally one or more pharmaceutically acceptable pigments. The one or more polymer agents of the pharmaceutically acceptable coating agent are preferably selected from one or more of the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, polyvinyl alcohol, polyethylene glycol, polyethylene glycol-polyvinyl alcohol graft copolymer, and polysorbate. The one or more pigments are preferably selected from the group of titanium dioxide, aluminium lakes, and iron oxides, preferably iron oxide yellow, iron oxide red, and iron oxide black.
According to an alternative or cumulative preferred embodiment of all aspects of the present invention the coating agent comprises or consists of
- hypromellose, macrogol 400, polysorbate 80 and titanium dioxide (commercially available as Opadry® White), preferably for inventive pharmaceutical tablet compositions comprising 16.05 mg or 32.1 mg eltrombopag olamine, or
- hypromellose, macrogol 400, titanium dioxide, iron oxide yellow and iron oxide red (commercially available as Opadry® Brown), preferably for inventive pharmaceutical tablet compositions comprising 64.2 mg eltrombopag olamine, or
- hypromellose, macrogol 400, titanium dioxide, iron oxide red and iron oxide black (commercially available as Opadry® Brown), preferably for inventive pharmaceutical tablet compositions comprising 96.3 mg eltrombopag olamine.
According to alternative or cumulative preferred embodiments of all aspects of the present invention, i. the total content of binder agent(s) is at least 0.5 wt.% or more, more preferably is in the range of 0.5 to 7 wt.%, more preferably 1 to 3 wt.% and/or
ii. the total content of diluent agent(s) including the reducing sugar amount is at least 5 wt.% or more, preferably is present in the range of 10 to 86 wt.%, alternatively in the range of 15 to 80 wt.%, alternatively in the range of 7 to 62 wt.%, alternatively in the range of 63 wt.% to 86 wt.% and/or iii. the total content of the disintegrant agent(s) is at least 3 wt.% or more, preferably is in the range of 4 to 15 wt.%, more preferably 5 to 14 wt.%, even more preferably 6 to 12 wt.% or alternatively is in the range of 3 to 5 wt.% and/or iv. the total content of the lubricant agent(s) is at least 0.5 wt.% or more, preferably is present in the range of 0.5 to 5 wt.%, preferably 0.8 to 3 wt.%, more preferably 0.9 to 1.5 wt.% and more preferably is 1 wt.% and/or v. the total content of the coating agent(s) is at least 2 wt.%, preferably in the range of 3 to 7 wt.%, more preferably 4 to 5 wt.%, respectively based on the total weight of the pharmaceutical tablet composition.
According to one embodiment of the present invention where the inventive tablet composition comprises 96.3 mg eltrombopag olamine (corresponding to 75 mg eltrombopag free acid) in the intragranular composition, the intragranular composition comprises in addition to eltrombopag olamine at least one binder agent as set out above in an amount of at least 1 wt.% or more, more preferably in the range of 1 wt.% to 5 wt.%, more preferably in the range of 2 wt.% to 4 wt.% based on the total weight of the produced pharmaceutical tablet composition, more preferably the binder agent is povidone. Furthermore, the intragranular composition comprises one, two or more further diluent agents as set out above in a total amount of at least 10 wt.%, more preferably 19 to 22 wt.%, more preferably the further diluent agent is microcrystalline cellulose or a combination of microcrystalline cellulose and xylitol. Furthermore, the intragranular composition comprises one, two or more disintegrant agents as set out above in a total amount of at least 1 wt.%, more preferably 2 wt.%, more preferably the disintegrant agent is sodium starch glycolate or croscarmellose sodium, more preferably sodium starch glycolate. In addition the extragranular composition comprises in addition to the reducing sugar content as diluent, one or more disintegrant agents, preferably in an amount of at least at least 3 wt.% or more, preferably 6 to 12 wt.%, more preferably the disintegrant agent is sodium starch glycolate or croscarmellose sodium or a mixture of sodium starch glycolate and croscarmellose sodium. Optionally the extragranular phase comprises one or more further binder agents, preferably in an amount of at least 0.5 wt.% or more, preferably 2 to 4 wt.%, more preferably povidone and optionally cro- spovidone. In addition the extragranular composition comprises at least one lubricant, preferably in an amount of at least 0.5 wt.% or more, preferably 0.9 to 1 .2 wt.%, more preferably the lubri-
cant is magnesium stearate. Furthermore the inventive tablet composition is film coated comprising suitable coating agents, preferably in an amount of least 2 wt.%, preferably 3 to 5 wt.%. The respective weight amounts as set out before respectively are based on the total weight of the inventive tablet composition. According to a furthermore preferred embodiment, the total weight of the inventive tablet composition is 363 mg.
According to one embodiment of the present invention where the inventive tablet composition comprises eltrombopag olamine in the extragranular composition, the intragranular composition comprises the reducing sugar, preferably lactose, more preferably lactose monohydrate, and a binder agent, preferably polyvinyl pyrrolidone, whereas the extragranular composition comprises in addition to a therapeutically active amount of eltrombopag olamine a diluent agent, preferably microcrystalline cellulose, and optionally one or more of the following pharmaceutically acceptable excipient agents, such as a binder agent, preferably polyvinyl pyrrolidone, a disintegrants agent, preferably sodium starch glycolate and a lubrication agent, preferably magnesium stearate. The resulting inventive tablet composition is preferably film coated with a suitable coating as disclosed above.
According to another embodiment of all aspects of the present invention as described herein before, the inventive pharmaceutical tablet composition additionally comprises or consists of a therapeutically effective amount of one or more additional active ingredients. The one or more additional active ingredients may be comprised in the intragranular composition or - in case of prevention of interaction between the active ingredients and eltrombopag olamine - in composition not comprising the eltrombopag olamine. Alternatively, the one or more additional active ingredients are simultaneously or sequentially co-administered in a separate pharmaceutical formulation. In a preferred embodiment, the one or more additional active ingredients are selected from constituents which are effective in the treatment of prophylaxis of thrombocytopenia, preferably adult chronic immune (idiopathic) thrombocytopenic purpura (ITP), acquired severe aplastic anaemia (SAA) and/or chronic hepatitis C virus (HCV) infection.
Accordingly, one or more additional active ingredients are selected from the group of corticosteroids, lithium carbonate, folate, rituximab, and immunoglobuline, in particular anti-Rh (D) immunoglobuline generally used to treat thrombocytopenia, in particular chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Additionally or alternatively one or more additional active ingredients are selected from the group of anti-infective agents, such as antibiotics and antifungal agents, immunosuppressive agents, such as anti-thymocyte globulin (ATG) and cyclosporine-A (CSA) and cytokine agents, such as
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), generally used to treat acquired severe aplastic anaemia (SAA).
Furthermore, one or more additional active ingredients are selected from the group of antiviral agents, such as daclatasvir, elbasvir, grazoprevir, ledipasvir, sofosbuvir, ombitasvir, paritaprevir, ritonavir, dasabuvir, simeprevir, sofosbuvir, velpatasvir, ribavirin, peginterferon alfa-2a or pegin- terferon alfa-2b generally used to treat chronic hepatitis C virus (HCV) infection.
The properties or the physical and chemical stability of the inventive pharmaceutical tablet composition may be tested in conventional manner, e.g. by measurement of appearance, hardness (or resistance to crushing), disintegration time, dissolution, friability, water content, assay for eltrombopag olamine and/or its degradation products (related substances), and/or uniformity of dosage units or mass after storage at controlled storage conditions; e.g. at intermediate and/or accelerated conditions according to ICH guideline Q1 A(R2) (i.e. at 25 °C / 60 % relative humidity (RH) and/or at 40 °C / 75 % RH). These tests shall be performed according to applicable pharmaceutical regulatory standards as described e.g. in ICH or EMA guidelines and/or the European Pharmacopeia (EP).
At least some of these attributes, i.e. properties or physical and chemical stability, preferably most of these attributes and most preferably all of these attributes of the inventive pharmaceutical tablet composition are stable over time and different controlled storage conditions. In a preferred embodiment the dissolution (profile) of the inventive pharmaceutical tablet composition according to the present invention, e.g. a tablet or film-coated tablet, is stable over at least 6 months when stored preferably in Alu-Alu blisters at intermediate or long-term storage conditions, i.e. 25 °C / 60 % RH or 40 °C / 75 % RH. More preferably, dissolution and further additional attributes such as, e.g., assay, related substances or uniformity of dosage units or mass are also stable after storage over at least 6 months when stored at intermediate or long-term storage conditions. The term "stable" in the context of the present invention means that a measured value falls within range of specified values determined in accordance with a respective applicable regulatory guideline, e.g. the European Pharmacopeia.
The inventive pharmaceutical tablet composition, preferably film-coated tablet, may vary in shape and be, e.g., round, oval, oblong, cylindrical, caplet shaped or any other suitable shape, preferably it is round or caplet shaped. Furthermore, the inventive pharmaceutical tablet composition comprises means for dividing the tablet, such as scores or engravings.
The inventive pharmaceutical tablet composition, preferably film-coated tablet, has a diameter ranging between 3.5 and 15 mm and most preferably between 5.5 and 7.0 mm for round tablets
and the dimension of a caplet is between 9.0 x 3.0 mm and 17.0 x 7.5 mm, preferably it is 12.7 x 5.9 mm. Thickness is ranging from 2.0 to 5.0 mm, preferably between 2.5 and 4.6 mm.
The inventive pharmaceutical tablet composition according to all aspects has a suitable hardness (or resistance to crushing), preferably the film-coated tablets may have a hardness (or resistance to crushing) of at least 40 N, preferably from 50 N to 130 N, more preferably 85 N to 1 10 N.
Furthermore, the inventive pharmaceutical tablet composition according to all aspects has a suitable disintegration time, preferably the film-coated tablets may have a disintegration time of at least 2 minutes, preferably in the range of 2 to 6 minutes.
Furthermore inventive pharmaceutical tablet composition, preferably film-coated tablet, may be colored and/or marked so as to impart an individual appearance and to make them instantly recognizable. The use of dyes can serve to enhance the appearance as well as to identify the inventive pharmaceutical composition. Dyes suitable for use in pharmacy typically include carot- enoids, iron oxides or chlorophyll. The inventive pharmaceutical tablet composition, preferably a film-coated tablet, may be marked using an imprint code.
The inventive pharmaceutical composition may be packed in any conventional packaging known in the art, for example blisters, polypropylene or polyethylene (e.g. HDPE, high density polyethylene) containers or glass bottles. Preferably the inventive tablet composition is preferably packed in a blister known in the art, e.g. sealed aluminum blister (Alu-Alu), Aluminum / Aluminum peel-push blisters or PVC/PE/PVDC/aluminum-blisters.
According to the third aspect of the present invention the inventive process of production of a pharmaceutical tablet comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars is characterized in that the process comprises or consists of the following steps: either a. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients, b. wet granulation of components mixed in step a) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, to form an intragranular composition, c. mixing one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally
further one or more pharmaceutically acceptable excipients to form an extragranular composition, d. mixing the extragranular composition of step c) with the intragranular composition of step b) to form a tablet composition, and e. compressing the tablet composition of step d) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the intragranular phase and one or more reducing sugars in the extragranular phase, or f. mixing one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally further one or more pharmaceutically acceptable excipients, g. wet granulation of components mixed in step f) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, to form an intragranular composition, h. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients to form an extragranular composition, i. mixing the extragranular composition of step h) with the intragranular composition of step g) to form a tablet composition, and j. compressing the tablet composition of step i) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the extragranular phase and one or more reducing sugars in the intragranular phase.
The preferred embodiments disclosed with respect to the inventive pharmaceutical tablet composition also apply in combination or separately with respect to the second aspect of the present invention.
Preferably the provided constituents, such as eltrombopag olamine, reducing sugars, disinte- grants, binders, diluents and coating agents are sifted prior to use, preferably they are sifted through a # 35 mesh (Tyler Equivalent) screen, which corresponds to a screen with an opening of 0.420 mm in diameter.
According to a preferred embodiment the provided constituents in step a) or in step f) are loaded into a high shear mixer granulator or an equivalent granulator and preferably mixed for 10, more preferably 5 minutes with impeller at preferably slow speed.
Subsequently, the suitable granulation fluid, preferably water or an aqueous solution of a binder, is added to the mixture of step a) or step f) in the high shear mixer granulator and the impeller is preferably used at low speed.
According to a preferred embodiment the granules obtained in step c) or in step h) after wet granulation are subsequently dried at suitable conditions.
In a further preferred embodiment the granules obtained in step c) or in step h) preferably dried are subsequently milled, preferably using a Quadro® Comil equipped with a suitable screen.
Subsequently, the (milled) granules forming the intragranular phase and sifted and admixed extragranular constituents are loaded into a blender and mixed preferably for 10 minutes according to step d) or step i). In case of using a lubricant, such as magnesium stearate, this constituent is preferably subsequently added to the blender and mixed preferably for further 5 minutes in step d) or step i).
Subsequently, the preferably lubricated mixture of step d) or step i) is compressed into the inventive pharmaceutical tablet composition preferably on a rotary tablet compression machine using suitable tooling and parameters in step e) or in step j).
The resulting inventive pharmaceutical tablet composition of step e) or step j) is furthermore preferably film coated in a subsequent step using one or more pharmaceutically acceptable excipients as suitable coating agent. The degradation of eltrombopag olamine may thereby be further reduced. Preferably the suitable coating agent comprises one or more polymers, optionally one or more plasticizers, and optionally one or more pigments. The preferred coating agents as disclosed with respect to the inventive pharmaceutical tablet composition can also be used with respect to the second aspect of the present invention.
As set out in the Example Section of the present application (see Part E, tables 1 and 2), the amount of impurities measured for the inventive pharmaceutical tablet compositions of the first and third aspect initially after production is below detection limit (BLD). When storing the inventive pharmaceutical tablet compositions under accelerated conditions at open exposure on a petri dish, the amount of impurities is still below detection limit for 40 % relative humidity (RH) and 50°C, 60°C and 70°C. When increasing the relative humidity to 75 % the impurities are detectable at a very low level for 50°C and an increased level for 75°C (see table 1 ). When using the regulatory accelerated stability assessment standards for Europe, the inventive pharmaceutical tablet compositions are sealed in Alu-Alu blisters and the amount of impurities is still below detection limit both after one or two months. Accordingly, the inventive pharmaceutical tablet compositions of the first and third aspect show a decreased degradation of eltrombopag olamine
as active ingredient in comparison to the lactose composition of the prior art (see Kapsi declaration), where the composition already initially after production comprises 1 .5 % total impurities. The reduced degradation of eltrombopag olamine may be due to the use of the inventive combination of the lactose with polyvinyl pyrrolidone and/or may be due to the inventive production process according to which the eltrombopag olamine constituent is formulated with polyvinyl pyrrolidone in one composition and the lactose is added together with further polyvinyl pyrrolidone in the other composition.
According to a fourth aspect of the present invention the inventive pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the composition comprising or consisting of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition or c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an intragranular composition and d) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an extragranular composition. is obtainable by use of the inventive production process.
According to a fifth aspect of the present invention the use the inventive pharmaceutical tablet composition is claimed, wherein the pharmaceutical tablet composition is used in the manufacture of a medicament for the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
According to a sixth aspect of the present invention the method of treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe
aplastic anaemia (SAA), comprises administering to a patient in need an inventive pharmaceutical tablet composition.
The present invention is explained further with the aid of the following non-limiting examples, illustrating the parameters of and compositions employed within the present invention. Unless stated otherwise, all data, in particular percentages, parts and ratios are by weight.
According to the present invention the individual features of the exemplary embodiments of the inventive pharmaceutical tablet composition and the inventive production process as disclosed in the detailed description or claims of the present application can respectively be separately combined with features of the further exemplary embodiments herein below.
Examples:
The eltrombopag olamine constituent used in the following example formulations F1 to 38 exhibits polymorphic form I.
Part A: General Procedure for the wet granulation compression (eltrombopag olamine intragranular / lactose extragranular)
Stage A: (Dry Mix)
1 . Sifted Eltrombopag olamine and intragranular excipients through #35 mesh.
2. Sifted materials of step-1 loaded into high shear mixer granulator and mixed for 5 minutes with impeller at slow speed.
Stage B: (Granulation)
3. Step-2 material was granulated with a suitable binder solution, e.g., water or an aqueous solution such as aqueous povidone solution, at impeller slow speed.
4. The granules of step-3 material were dried in a suitable equipment to get required loss on drying.
5. The dried granules of step-4 were milled using Quadro® Comil equipped with suitable screen.
Stage C: (Blending)
6. Extragranular materials were sifted through #35 mesh.
7. Milled granules of step 5 and sifted extragranular materials of step 6 were loaded into the blender and mixed for 10 min.
Stage D: (Lubrication)
8. Magnesium stearate sifted through #35 mesh and added to blend mixture of step 7 and lubricated for 5 minutes.
9. The blend mixture of step 8 was compressed into tablets on rotary tablet compression machine using suitable tooling and parameters.
Stage E: Film-Coating
10. Core tablets of step 9 were coated in coating pan using corresponding Opadry® suspension.
Part B: Process of production of inventive pharmaceutical tablet compositions (eltrombopag olamine intragranular / lactose extragranular)
The following inventive pharmaceutical tablet compositions F1 -F37 are produced in accordance with the general procedure as set out in Part A above:
Example F1 : inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredierrts F1 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902
Cellulose, Microcrystalline Ph. Eur. 82.698
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
9.600
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. 79.300
Microcelac® (Lactose monohydrate in an amount of 75 wt.
% and microcrystalline cellulose 25 wt. % respectively 48.000
based on the total weight of Microcelac®) ln-house
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Pink ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F2: inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F2 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902
Cellulose, Microcrystalline Ph. Eur. 1 18.698
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
9.600
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. 79.300
Lactose monohydrate Ph. Eur. (Tablettose 100) 12.000
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Pink ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F3: inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, microcrystalline cellulose, polyvinyl pyrrolidone (povidone), crosslinked insoluble polyvinylpyrrolidone (crospovidone), sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
I gredients F3 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902
Cellulose, Microcrystalline Ph. Eur. 91.698
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
9.600
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. 79.300
Ludipress® (Lactose monohydrate in an amount of 93 wt.
%, polyvinyl pyrrolidone, Povidone, Kollidon® 30 in an
amount of 3.5 wt. % and crosslinked insoluble polyvi39.000
nylpyrrolidone, Crospovidone, Kollidon® CL 3.5 wt. %
respectively based on the total weight of Ludipress®)
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Pink ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F4: inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F4 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902
Cellulose, Microcrystalline Ph. Eur. 94.698
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
9.600
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. 79.300
Lactose monohydrate Ph. Eur. (Tablettose 100) 36.000
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Pink ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F5: inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, xylitol, sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intra- granular phase
Ingredients F5 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902
Cellulose, Microcrystalline Ph. Eur. 73.000
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
9.600
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Xylitol Ph.Eur. 92.998
Lactose monohydrate Ph.Eur. (Tablettose 100) 44.000
Sodium starch glycolate Type-A Ph.Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph.Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph.Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F6: inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, xylitol, sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intra- granular phase
Ingredients F6 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902
Cellulose, Microcrystalline Ph. Eur. 73.000
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
9.600
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Xylitol Ph.Eur. 81.998
Lactose monohydrate Ph.Eur. (Tablettose 100) 55.000
Sodium starch glycolate Type-A Ph.Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph.Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph.Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F7: inventive pharmaceutical film-coated tablet composition comprising lactose mono- hydrate, xylitol, sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intra- granular phase gr¾dlents
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902
Cellulose, Microcrystalline Ph. Eur. 73.000
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
9.600
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Xylitol Ph.Eur. 9.998
Lactose monohydrate Ph.Eur. (Tablettose 100) 127.000
Sodium starch glycolate Type-A Ph.Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph.Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph.Eur. q.s.
Film-coated tablet weight (mg) 363.000
Examples F8 and F9: inventive pharmaceutical film-coated tablet compositions comprising co- processed lactose comprising lactose monohydrate, polyvinyl pyrrolidone (povidone) and cross- linked insoluble polyvinyl pyrrolidone (crospovidone), sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F8 (mg/unit) Fi ingtoriit
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902 95.703
Cellulose, Microcrystalline Ph. Eur. 73.000 72.365
Polyvinyl pyrrolidone, Povidone Ph. Eur.
9.600 9.600
(Plasdone K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s. q.s.
Stage-C (Blending)
Ludipress® (Lactose monohydrate in an
amount of 93 wt. %, polyvinyl pyrrolidone,
Povidone, Kollidon® 30 in an amount of 3.5
wt. % and crosslinked insoluble polyvinylpyr137.000 138.832 rolidone, Crospovidone, Kollidon® CL 3.5 wt.
% respectively based on the total weight of
Ludipress®)
Sodium starch glycolate Type-A Ph. Eur.
28.000 28.000
(Explotab)
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500 3.500
Core Tablet weight (mg) 348.000 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000 15.000
Water, Purified Ph. Eur. q.s. q.s.
Film-coated tablet weight (mg) 363.000 363.000
Examples F10 and F11 : inventive pharmaceutical film-coated tablet compositions comprising lactose monohydrate, polyvinyl pyrrolidone (povidone), sodium starch glycolate and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F10 (mg/unit) F11 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.902 95.703
Cellulose, Microcrystalline Ph. Eur. 73.000 72.365
Polyvinyl pyrrolidone, Povidone Ph. Eur.
9.600 9.600
(Plasdone K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s. q.s.
Stage-C (Blending)
Lactose monohydrate Ph. Eur. (Tablettose
127.000 128.832
100)
Polyvinyl pyrrolidone, Povidone Ph. Eur.
9.998 10.000
(Plasdone K29/32)
Sodium starch glycolate Type-A Ph. Eur.
28.000 28.000
(Explotab)
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500 3.500
Core Tablet weight (mg) 348.000 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000 15.000
Water, Purified Ph. Eur. q.s. q.s.
Film-coated tablet weight (mg) 363.000 363.000
Example F12: inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose, xylitol and polyvinyl pyrroli- done (povidone) in intragranular phase
Ingredients F12 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.251
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 45.000
Xylitol 80.000
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
10.000
K29/32)
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 27.900
Lactose monohydrate Ph. Eur. 57.349
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F13: inventive pharmaceutical film-coated tablet composition comprising anhydrous lactose, sodium starch glycolate and magnesium stearate in extragranular phase and eltrom- bopag olamine, microcrystalline cellulose, sodium starch glycolate and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F13 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.338
Cellulose, Microcrystalline Ph. Eur. 73.000
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
20.000
K29/32)
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 14.000
Stage-B: (Binder Solution / Granulation)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Lactose anhydrous Ph. Eur. (Supertab 21 AN) 127.162
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 14.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F14: inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose, and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F14 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.251
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 18.269
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 7.000
Stage-B: (Binder Solution / Granulation)
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
10.000
K29/32)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 54.000
Lactose monohydrate Ph. Eur. (Flowlac 90) 137.980
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 21 .000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F15: inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate in extra- granular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F15 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.251
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 36.269
Stage-B: (Binder Solution / Granulation)
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
10.000
K29/32)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 36.000
Lactose monohydrate Ph. Eur. (Flowlac 90) 137.980
Croscarmellose sodium Ph. Eur. (Ac-Di-Sol) 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F16: inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, crospovidone and magnesium stearate in extragranular phase and eltrombopag olamine, microcrystalline cellulose and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients F16 (mg/unit)
Stage-A: (Dry Mix)
Eltrombopag Olamine, ln-house 96.251
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 36.269
Stage-B: (Binder Solution / Granulation)
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
10.000
K29/32)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 36.000
Lactose monohydrate Ph. Eur. (Flowlac 90) 137.980
Crospovidone Ph. Eur. 28.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Examples F17 to F20: inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, polyvinyl pyrrolidone (povidone), sodium starch glycolate and magnesium stearate in extragranular phase and 16 mg, 31 .1 mg or 63.2 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg or 50 mg eltrombopag) in combination with microcrystalline cellulose and povidone in intragranular phase
Ingredients F17 F18 F19 F20
Stage-A: (Dry Mix) (mg/unit) (mg/unit) (mg/unit) (mg/unit)
Eltrombopag Olamine, ln-house 63.167 31.084 16.042 16.042
Cellulose, Microcrystalline Ph. Eur.
73.000 73.00 73.00 36.500 (Comprecel M 102 D+)
Povidone Ph. Eur. (Plasdone K29/32) 9.600 9.60 9.60 4.800
Water, Purified Ph. Eur. q.s. q.s. q.s. q.s.
Stage-B (Blending)
Lactose monohydrate Ph. Eur. (Tablettose
160.733 192.816 207.858 95.908 100)
Povidone Ph. Eur. (Plasdone K29/32) 10.000 10.000 10.000 5.000
Sodium starch glycolate Type-A Ph. Eur. (Ex-
28.000 28.000 28.000 14.000 plotab)
Stage-C (Lubrication)
Magnesium stearate Ph. Eur. 3.500 3.500 3.500 1 .750
Core Tablet weight (mg) 348.000 348.000 348.000 348.000
Stage-D (Film-coating)
Opadry ® Brown ln-house 15.000 - - -
Opadry ® White ln-house - 15.000 15.000 7.500
Water, Purified Ph. Eur. q.s. q.s. q.s. q.s.
Film-coated tablet weight (mg) 363.000 363.000 363.000 363.000
Examples F21 and F22: inventive pharmaceutical film-coated tablet composition comprising Ludipress® (93 wt.% lactose monohydrate, 3.5 wt.% polyvinyl pyrrolidone (Kollidon 30) and 3.5 wt.% crospovidone (Kollidon CL)) and sodium starch glycolate and magnesium stearate in ex- tragranular phase and 16 mg eltrombopag olamine (equivalent to 12.5 mg eltrombopag) in combination with microcrystalline cellulose and povidone in intragranular phase
Ingredients F21 F22
Stage-A: (Dry Mix) (mg/unit) (mg/unit)
Eltrombopag Olamine, ln-house 16.042 16.042
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 73.000 36.500
Povidone Ph. Eur. (Plasdone K29/32) 9.600 4.80
Water, Purified Ph. Eur. q.s. q.s.
Stage-B (Blending)
Ludipress® (93% Lactose monohydrate, 3.5% Povidone, and 3.5%
217.858 100.908 Crospovidone)
Povidone Ph. Eur. (Plasdone K29/32) - -
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000 14.000
Stage-C (Lubrication)
Magnesium stearate Ph. Eur. 3.500 1 .750
Core Tablet weight (mg) 348.000 174.000
Stage-D (Film-coating)
Opadry ® White ln-house 15.000 7.500
Water, Purified Ph. Eur. q.s. q.s.
Film-coated tablet weight (mg) 363.000 181.500
Examples F23 and F24: inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, copovidone, sodium starch glycolate and magnesium stearate in extra- granular phase and 16 mg eltrombopag olamine (equivalent to 12.5 mg eltrombopag) in combination with microcrystalline cellulose and copovidone in intragranular phase
Ingredients F23 F24
Stage-A: (Dry Mix) (mg/unit) (mg/unit)
Eltrombopag Olamine, ln-house 16.042 16.042
Cellulose, Microcrystalline Ph. Eur.
73.000 36.500 (Comprecel M 102 D+)
Copovidone Ph. Eur. (Plasdone S 630) 9.600 4.800
Water, Purified Ph. Eur. q.s. q.s.
Stage-B (Blending)
Lactose monohydrate Ph. Eur. (Tablettose 100) 207.858 95.908
Copovidone Ph. Eur. (Plasdone S 630) 10.000 5.000
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000 14.000
Stage-C (Lubrication)
Magnesium stearate Ph. Eur. 3.500 1 .750
Core Tablet weight (mg) 348.000 174.000
Stage-D (Film-coating)
Opadry ® White ln-house 15.000 7.500
Water, Purified Ph. Eur. q.s. q.s.
Film-coated tablet weight (mg) 363.000 181.500
Examples F25 to F28: inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate and magnesium stearate in extragranular phase and 16 mg, 31 .9 mg, 63.2 mg or 95.7 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg, 50 mg or 75 mg eltrombopag) in combination with microcrystalline cellulose, polyvinyl pyrrolidone and sodium starch glycolate in intragranular phase
Ingredients F25 F26 F27 F28
Stage-A: (Dry Mix) (mg/unit) (mg/unit) (mg/unit) (mg/unit)
Eltrombopag Olamine, ln-house 95.703 63.802 31.901 15.951
Cellulose, Microcrystalline Ph. Eur.
18.000 12.000 6.000 3.000 (Comprecel M 101 D+)
Sodium starch glycolate Type-A Ph. Eur.
7.000 4.670 2.333 1 .167 (Explotab)
Stage-B (Binder solution)
Povidone Ph. Eur. (Plasdone K29/32) 10.000 6.667 3.333 1 .167
Water, Purified Ph. Eur. q.s. q.s. q.s. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur.
54.000 36.000 18.000 9.000 (Avicel PH 200
Lactose monohydrate Ph. Eur.
126.797 84.530 42.267 21.133 (Tablettose 80)
Croscarmellose sodium Ph. Eur.
5.000 3.333 1 .667 0.833 (Ac-di-sol SD 711)
Sodium starch glycolate Type-A Ph. Eur.
28.000 18.667 9.333 4.667 (Explotab)
Stage-D (Lubrication)
Magnesium stearate Ph. Eur. 3.5000 2.333 1 .167 0.583
Core Tablet weight (mg) 348.000 232.000 116.000 58.000
Continuation of Ingredients F25 F26 F27 F28
Stage-E (Film-coating)
Opadry ® Brown 85F565229 In-house 15.000 - - -
Opadry ® Brown 85F565230 In-house - 10.000 - -
Opadry ® White In-house - - 5.000 2.500
Water, Purified Ph. Eur. q.s. q.s. q.s. q.s.
Film-coated tablet weight (mg) 363.000 242.000 121.000 60.500
Examples F29 to F32: inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate and magnesium stearate in extragranular phase and 16 mg, 31.9 mg, or 63.2 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg, or 50 mg eltrombopag) in combination with microcrystalline cellulose, polyvinyl pyrrolidone (povidone) and sodium starch glycolate in intragranular phase
Ingredients F29 F30 F31
Stage-A: (Dry Mix) (mg/unit) (mg/unit) (mg/unit)
Eltrombopag Olamine, ln-house 63.802 31.901 15.951
Cellulose, Microcrystalline Ph. Eur.
12.000 6.000 3.000 (Comprecel M 101 D+)
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 4.667 2.333 1 .167
Stage-B (Binder solution)
Povidone Ph. Eur. (Plasdone K29/32) 6.667 3.333 1 .667
Water, Purified Ph. Eur. q.s. q.s. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. (Avicel PH 200j 54.000 54.000 27.000
Lactose monohydrate Ph. Eur. (Tablettose 80) 170.365 213.932 106.966
Croscarmellose sodium Ph. Eur. (Ac-di-sol SD 711) 5.000 5.000 2.500
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000 28.000 14.000
Stage-D (Lubrication)
Magnesium stearate Ph. Eur. 3.500 3.500 1 .750
Core tablet weight (mg) 348.000 348.000 174.000
Stage-E (Film-coating)
Opadry ® Brown ln-house 15.000 - -
Opadry ®White ln-house - 15.000 7.500
Water, Purified Ph. Eur. q.s. q.s. q.s.
Film-coated tablet weight (mg) 363.000 363.000 181.500
Example F32: inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, mannitol, sodium starch glycolate and magnesium stearate in extragranular phase and 96.25 mg eltrombopag olamine (equivalent to 75 mg eltrombopag), microcrystalline cellulose, sodium starch glycolate, and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients ., :;*¾¾ ,
Stage-A: (Dry Mix) (mg/unit)
Eltrombopag Olamine, ln-house 96.251
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 18.269
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 7.000
Stage-B: (Binder Solution / Granulation)
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
10.000
K29/32)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Mannitol Ph. Eur. (Pearlitol SD 200) 54.000
Lactose monohydrate Ph. Eur. (Flowlac 90) 134.980
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 24.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Example F33: inventive pharmaceutical film-coated tablet composition comprising lactose mon- ohydrate, microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium and magnesium stearate in extragranular phase and 96.25 mg eltrombopag olamine (equivalent to 75 mg eltrombopag), microcrystalline cellulose, and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients
Stage-A: (Dry Mix) (mg/unit)
Eltrombopag Olamine, ln-house 96.251
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 18.269
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 7.000
Stage-B: (Binder Solution / Granulation)
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
10.000
K29/32)
Water, purified Ph. Eur. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 54.000
Lactose monohydrate Ph. Eur. (Flowlac 90) 120.980
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000
Croscarmellose sodium Ph. Eur. (Ac-Di-Sol) 10.000
Stage-D (Blending & Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-E (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Examples F34 to F37: inventive pharmaceutical film-coated tablet composition comprising lactose monohydrate, microcrystalline cellulose, sodium starch glycolate and magnesium stea- rate in extragranular phase and 16 mg, 31.9 mg, 63.2 mg or 95.7 mg eltrombopag olamine (equivalent to 12.5 mg, 25 mg, 50 mg or 75 mg eltrombopag) in combination with microcrystalline cellulose, polyvinyl pyrrolidone and sodium starch glycolate in intragranular phase
Ingredients F34 F35 F36 F37
Stage-A: (Dry Mix) (mg/unit) (mg/unit) (mg/unit) (mg/unit)
Eltrombopag Olamine, ln-house 95.703 63.802 31.901 15.951
Cellulose, Microcrystalline Ph. Eur.
18.000 12.000 6.000 3.000 (Comprecel M 101 D+)
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 7.000 4.667 2.333 1 .167
Stage-B (Binder solution)
Povidone Ph. Eur. (Plasdone K29/32) 10.000 6.667 3.333 1 .667
Water, Purified Ph. Eur. q.s. q.s. q.s. q.s.
Stage-C (Blending)
Cellulose, Microcrystalline Ph. Eur.
54.000 54.000 54.000 27.000 (Avicel PH 105;
Lactose monohydrate Ph. Eur.
149.797 193.364 236.933 1 18.467 (Flowlac 90)
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 10.000 10.000 10.000 5.000
Stage-D (Lubrication)
Magnesium stearate Ph. Eur. 3.500 3.500 3.500 1 .750
Core Tablet weight (mg) 348.000 348.000 348.000 174.000
Continuation of Ingredients F34 F35 F36 F37
Stage-E (Film-coating)
Opadry ® II Brown 85F565229 In-house (Polyvinyl
alcohol-partially hydrolyzed, Macrogol 3350, Titanium
15.000 - - - dioxide, Talc, Iron oxide red, Iron oxide yellow, Iron
oxide black)
Opadry ® II Brown 85F565230 In-house (Polyvinyl
alcohol-partially hydrolyzed, Macrogol 3350, Titanium
- 15.000 - - dioxide, Talc, Iron oxide red, Iron oxide yellow, Iron
oxide black)
Opadry ® White YS-1 -7706-G In-house (Hypromellose
- - 15.000 7.500 2910, Macrogol 400, Titanium dioxide, Polysorbate 80)
Water, Purified Ph. Eur. q.s. q.s. q.s. q.s.
Film-coated tablet weight (mg) 363.000 363.000 363.000 181.500
Part C: General Procedure for the wet granulation compression (lactose intragranular / eltrombopag olamine extragranular)
Stage A: (Dry Mix / Wet Granulation)
1 . Stage-A materials were sifted through #35 mesh.
2. Sifted materials of step-1 loaded into high shear mixer granulator and mixed for 5 minutes with impeller at slow speed.
3. Step-2 material was granulated with a suitable binder solution, e.g., water or an aqueous solution such as aqueous povidone solution, at impeller slow speed.
4. The granules of step-3 material were dried in a suitable equipment to get required loss on drying.
5. The dried granules of step-4 were milled using Quadro® Comil equipped with suitable screen.
Stage B: (Blending)
6. Extragranular Stage B materials were sifted through #35 mesh.
7. Dried milled granules of step 5 and sifted extragranular materials of step 6 were loaded into the blender and mixed for 10 min.
Stage C: (Lubrication)
8. Lubrication material of Stage C, e.g., magnesium stearate, was sifted through #35 mesh and added to blend mixture of step 7 and lubricated for 5 minutes.
9. The blend mixture of step 8 was compressed into tablets on rotary tablet compression machine using suitable tooling and parameters.
Stage D: Film-Coating
10. Core tablets of step 9 were coated in coating pan using corresponding Opadry® suspension, e.g., aqueous Opadry® brown suspension.
Part D: Process of production of inventive pharmaceutical tablet compositions (lactose intragranular / eltrombopag olamine extragranular)
The following inventive pharmaceutical tablet composition F38 is produced in accordance with the general procedure as set out in Part C above:
Example F38: inventive pharmaceutical film-coated tablet composition comprising 96.25 mg eltrombopag olamine (equivalent to 75 mg eltrombopag), microcrystalline cellulose, polyvinyl pyrrolidone (povidone) and magnesium stearate in extragranular phase and lactose monohy- drate and polyvinyl pyrrolidone (povidone) in intragranular phase
Ingredients , F38,; .
Stage-A: (Dry Mix / Wet Granulation) (mg/unit)
Lactose monohydrate Ph. Eur. (Flowlac 90) 193.037
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
4.800
K29/32)
Water, purified Ph. Eur. q.s.
Stage-B (Blending)
Eltrombopag Olamine, ln-house 95.703
Cellulose, Microcrystalline Ph. Eur. (Comprecel M 102 D+) 18.160
Sodium starch glycolate Type-A Ph. Eur. (Explotab) 28.000
Polyvinyl pyrrolidone, Povidone Ph. Eur. (Plasdone
4.800
K29/32)
Stage-C (Lubrication)
Magnesium stearate Ph. Eur. 3.500
Core Tablet weight (mg) 348.000
Stage-D (Film-coating)
Opadry® Brown ln-house 15.000
Water, Purified Ph. Eur. q.s.
Film-coated tablet weight (mg) 363.000
Part E: Stability and dissolution of inventive pharmaceutical tablet compositions
An Accelerated Stability Assessment Program (ASAP) for up to 2-3 weeks under open exposure, according to Waterman 201 1 (Waterman KC, The application of the Accelerated Stability Assessment Program (ASAP) to quality by design (QbD) for drug product stability, AAPS PharmSciTech, Vol. 12, No. 3, September 2011) is usually applied for a quick estimation of chemical stability (cf. Table 1 ). A precise relative comparison of stability of two different compositions, or more precise shelf-life prediction compared with long-term and accelerated stability in commercial blister packaging can be conducted according to ICH guideline Q1A(R2) (cf. Table 2).
Table 1. ASAP Stability data of Coated Tablets, Open Exposure:
Condition Days % Unspecified impurity % Total impurities
# F8 F10 F8 F10
Initial - BDL BDL BDL BDL
50°C/75%RH 21 Days 1 .44 1 .71 1 .53 1 .71
60°C/40%RH 21 Days 0.22 0.65 0.22 0.83
Condition Days % Unspecified impurity % Total impurities
# F25 F26 F25 F26
Initial - BDL BDL BDL BDL
50°C/75%RH 14 Days 0.60 BDL 0.94 BDL
60°C/40%RH 14 Days 0.52 0.46 0.76 0.81
70°C/5%RH 14 Days 0.09 0.37 0.19 0.46
Condition Days % Unspecified impurity % Total impurities
# F29 F31 F29 F31
Initial - BDL BDL BDL BDL
50°C/75%RH 14 Days 0.53 0.77 0.94 1 .65
60°C/40%RH 14 Days 0.45 0.60 0.70 0.86
70°C/5%RH 14 Days 0.19 0.24 0.39 0.54
The amount of impurities measured for the inventive pharmaceutical tablet compositions initially after production are below detection limit (BDL). The impurities measured in the open exposure testing were found to be higher the higher the humidity was. At lower humidity impurities have not been detected even at higher temperatures.
The above data already suggests that inventive eltrombopag olamine tablets packaged preferably in Alu-Alu blister, will show less impurities at real time storage condition, as the water vapor transmission rate (WVTR) for Alu-Alu blister is reduced to the minimum. The finding is confirmed with the accelerated stability testings shown in table 2 below.
Accordingly, for tablets packaged in the commercially representative packaging material under accelerated storage conditions, which are also used in the Kapsi declaration, the degradation of eltrombopag olamine as active ingredient in the inventive pharmaceutical tablet compositions is decreased in comparison to the lactose containing tablet composition of the prior art (see Kapsi declaration), where the tablet composition already initially after production comprises 1.5 % total impurities.
Table 2. Accelerated stability data of film-coated inventive tablets in Alu-Alu blister:
The physical and chemical stability of the inventive pharmaceutical tablet composition may be tested in conventional manner, in particular at accelerated conditions according to ICH guideline Q1A(R2) (i.e. at 25 °C / 60 % relative humidity (RH) and/or at 40 °C / 75 % RH). The accelerated stability tests as set out in table 2 above have been performed according to applicable pharmaceutical regulatory standards as described e.g. in ICH or EMA guidelines and/or the European Pharmacopeia (EP), wherein the inventive pharmaceutical tablet composition have been packed in Alu-Alu blisters.
The amount of impurities measured for the inventive pharmaceutical tablet compositions initially after production are below detection limit. When using the regulatory accelerated stability assessment standards for Europe as storage conditions, the inventive pharmaceutical tablet compositions are sealed in Alu-Alu blisters and the amount of impurities is still below detection limit after one or two or six months storage. Accordingly, the inventive pharmaceutical tablet compositions show no degradation within six month accelerated storage.
The fact that no degradation products of eltrombopag olamine could be detected may be due to the separation of eltrombopag olamine in the intragranular phase and the reducing sugar, preferably lactose in the extragranular phase. When using higher amounts of reducing sugar, in particular lactose, the additional use of a polymeric binder agent, in particular povidone, in the intragranular phase and/or extragranular phase, in particular the extragranular phase and optionally the intragranular phase seems to be advantageous to further facilitate the decreased degradation of eltrombopag olamine in the inventive tablet composition.
Table 3. Dissolution testing:
Dissolution testing according to tables 3-7 was performed using USP Apparatus II, 50 rpm, 900 ml of phosphate buffer pH 6.8 containing 0.5% Tween 80 as recommended for Eltrombopag Olamine in the FDA Dissolution Methods Database on the FDA webpage. Based on the Ph. Eur. (5.17.1 ) recommendation for immediate-release dosage forms, the specification is set as at least 75% of the active substance is dissolved within 45 minutes.
The experimental data of table 3 shows that 75 wt.% or more, preferably more than 80 wt.%, more preferably more than 90 wt.% of eltrombopag olamine of the inventive pharmaceutical tablet compositions is dissolved within 45 minutes in accordance with the regulatory standard test.
With respect to inventive eltrombopag tablet compositions F9 and F1 1 , the test results could be confirmed after 1 month storage in Alu-Alu blister under accelerated condition at 40°C and 75 % relative humidity. With respect to inventive eltrombopag tablet composition F1 1 , the test results could be confirmed also after 6 months storage in Alu-Alu blister under accelerated condition at 40°C and 75 % relative humidity. Accordingly, the inventive tablet compositions are not only stable over preferably 6 month, they also comply with the regulatory standards for dissolution testings, where at least 75 wt.% of eltrombopag olamine needs to be dissolved within 45 minutes.
In addition dissolution testings concerning, e.g. F17, F18, F20, F21 , F23, and F25-F38, show that after 45 minutes at least 75 wt.%, preferably between 86 and 100 wt.% eltrombopag olamine based on the total weight of the eltrombopag olamine content in the tablet is dissolved.
With respect to inventive eltrombopag tablet composition F34, the test results could be confirmed after 1 month storage in Alu-Alu blister under accelerated condition at 40°C and 75 % relative humidity. With respect to inventive eltrombopag tablet composition F38, the test results could be confirmed after 14 days storage under open exposure stress condition at 50°C and 75 % relative humidity.
Furthermore, the dissolution of the inventive formulations of the present invention is comparable to the commercially available reference product Revolade® film-coated tablets (FCTs), as shown below in tables 4, 5, 6, and 7 for the 75 mg, 50 mg, 25 mg, and 12.5 mg strength, correspondingly.
Table 4. Comparative dissolution of Eltrombopag 75 mg FCTs with Revolade® 75 mg:
Cumulative wt.% eltrombopag olamine
Composition
dissolved after 45 minutes
Revolade® 75 mg (batch MX4H) 97
F25 93
F32 94
F33 95
F34 98
F38 100
Table 5. Comparative dissolution of Eltrombopag 50 mg FCTs with Revolade® 50 mg:
Table 6. Comparative dissolution of Eltrombopag 25 mg FCTs with Revolade® 25 mg:
Table 7. Comparative dissolution of Eltrombopag 12.5 mg FCTs with Revolade® 12.5 mg:
Cumulative wt.% eltrombopag olamine
Composition
dissolved after 45 minutes
Revolade® 12.5 mg (batch 9Y3C) 87
F20 88
F21 94
F23 92
F28 93
F31 91
F37 97
Claims
1 . Pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the composition comprises or consists of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition, or c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an intragranular composition and d) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an extragranular composition.
2. Pharmaceutical tablet composition according to claim 1 , wherein the reducing sugar in the extragranular composition comprises or consists of lactose selected from the group consisting of lactose monohydrate, anhydrous lactose, spray dried lactose and co-processed lactose.
3. Pharmaceutical tablet composition according to claim 1 or 2, wherein the reducing sugar content is greater than 5 wt.%, preferably at least 9 wt.%, more preferably in the range of 15 to 75 wt.% alternatively 40 to 70 wt.% respectively based on the total weight of the pharmaceutical tablet composition.
4. Pharmaceutical tablet composition according to any one of claims 1 to 3, wherein the further one or more pharmaceutically acceptable excipients in the intragranular and optionally extragranular composition are selected from suitable binder agents, preferably one or more binder agents are selected from the group consisting of povidone, copovidone, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methyl- cellulose, hydroxypropyl starch, polyethylene oxide, more preferably one or two binder agents are selected from povidone and copovidone or one or more binder agents are se-
lected from the group consisting of povidone, copovidone, polyvinyl alcohol, polyethylene glycol, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyethylene glycol-polyvinyl alcohol graft copolymer, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, and hydroxypropyl starch.
5. Pharmaceutical tablet composition according to any one of claims 1 to 4, wherein the further one or more pharmaceutically acceptable excipients in the intragranular and/or extragranular composition, preferably in the intragranular and extragranular composition are selected from suitable further diluent agents, preferably one or more further diluent agents are selected from the group consisting of erythritol, isomalt, maltitol, xylitol, microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactitol, mannitol, sorbitol, maltodextrin more preferably one, two or more further diluent agents are selected from erythritol, isomalt, maltitol, xylitol, and microcrystalline cellulose, even more preferably the further diluent agents are selected from microcrystalline cellulose and one, two or more selected from erythritol, isomalt, maltitol and xylitol, preferably xylitol.
6. Pharmaceutical tablet composition according to any one of claims 1 to 5 wherein the further one or more pharmaceutically acceptable excipients in the intragranular and/or extragranular composition, preferably in the extragranular composition are selected from suitable disintegrant agents, preferably one or more disintegrant agents are selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium, more preferably one or two selected from sodium starch glycolate and crospovidone or low-substituted hydroxypropyl cellulose.
7. Pharmaceutical tablet composition according to any one of claims 1 to 6, wherein the further one or more pharmaceutically acceptable excipients in the extragranular composition are selected from suitable lubricant agents, preferably selected from magnesium stea- rate, stearic acid, and sodium stearyl fumarate, more preferably magnesium stearate.
8. Pharmaceutical tablet composition according to any one of claims 1 to 7, wherein the pharmaceutical tablet composition is film coated with a suitable coating agent, preferably comprising one or more pharmaceutically acceptable polymers, optionally one or more pharmaceutically acceptable plasticizers, and optionally one or more pharmaceutically acceptable pigments.
9. Pharmaceutical tablet composition according to any one of claims 4 to 8, wherein i. the total content of binder agent(s) is at least 0.5 wt.% or more, more preferably is in the range of 0.5 to 7 wt.%, more preferably 1 to 3 wt.% and/or
ii. the total content of diluent agent(s) including the reducing sugar amount is at least 5 wt.% or more, preferably is present in the range of 10 to 86 wt.%, alternatively in the range of 15 to 80 wt.%, alternatively in the range of 7 to 62 wt.%, alternatively in the range of 63 wt.% to 86 wt.% and/or iii. the total content of the disintegrant agent(s) is at least 3 wt.% or more, preferably is in the range of 4 to 15 wt.%, more preferably 5 to 14 wt.%, even more preferably 6 to 12 wt.% or alternatively is in the range of 3 to 5 wt.% and/or iv. the total content of the lubricant agent(s) is at least 0.5 wt.% or more, preferably is present in the range of 0.5 to 5 wt.%, preferably 0.8 to 3 wt.%, more preferably 0.9 to 1 .5 wt.% and more preferably is 1 wt.% and/or v. the total content of the coating agent(s) is at least 2 wt.%, preferably in the range of 3 to 7 wt.%, more preferably 4 to 5 wt.%, respectively based on the total weight of the pharmaceutical tablet composition.
10. Pharmaceutical tablet composition according to any one of the preceding claims for use in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
1 1 . Process of production of a pharmaceutical tablet comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the process comprises the following steps: either a. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients, b. wet granulation of components mixed in step a) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, in a suitable amount to form an intra- granular composition, c. mixing one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients to form an extragranular composition, d. mixing the extragranular composition of step c) with the intragranular composition of step b) to form a tablet composition, and
e. compressing the tablet composition of step d) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the intragranular phase and one or more reducing sugars in the extragranular phase, or f. mixing one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose, preferably lactose and optionally further one or more pharmaceutically acceptable excipients, g. wet granulation of components mixed in step f) with a suitable granulation fluid, preferably water or an aqueous solution of a binder, to form an intragranular composition, h. mixing a therapeutically effective amount of eltrombopag olamine and one or more pharmaceutically acceptable excipients to form an extragranular composition, i. mixing the extragranular composition of step h) with the intragranular composition of step g) to form a tablet composition, and j. compressing the tablet composition of step i) to form the pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient in the extragranular phase and one or more reducing sugars in the intragranular phase.
Process according to claim 12, wherein the compressed pharmaceutical tablet composition of step d) is in a subsequent step e) film coated with one or more pharmaceutically acceptable excipients.
Pharmaceutical tablet composition comprising eltrombopag olamine as active ingredient and one or more pharmaceutically acceptable excipients including one or more reducing sugars, characterized in that the composition comprising or consisting of either a) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an intragranular composition, and b) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an extragranular composition or
c) one or more reducing sugars, preferably selected from the group consisting of lactose, maltose, glucose, arabinose, and fructose and optionally further one or more pharmaceutically acceptable excipients in an intragranular composition and d) eltrombopag olamine in a therapeutically effective amount and one or more pharmaceutically acceptable excipients in an extragranular composition is obtainable by the production process according to claim 1 1 or 12.
14. Use of a pharmaceutical tablet composition according to any one of claims 1 to 9 or 13, wherein the pharmaceutical tablet composition is used in the manufacture of a medicament for the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA).
15. A method of treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe aplastic anaemia (SAA), comprising administering to a patient in need a pharmaceutical tablet composition in accordance with any one of claims 1 to 9 or 13.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22157319.9A EP4019009A1 (en) | 2017-04-26 | 2018-03-07 | Pharmaceutical tablet composition comprising eltrombopag olamine |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201711014792 | 2017-04-26 | ||
| EP17181421.3A EP3395331B1 (en) | 2017-04-26 | 2017-07-14 | Pharmaceutical tablet composition comprising eltrombopag olamine |
| PCT/EP2018/055618 WO2018197088A1 (en) | 2017-04-26 | 2018-03-07 | Pharmaceutical tablet composition comprising eltrombopag olamine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22157319.9A Division EP4019009A1 (en) | 2017-04-26 | 2018-03-07 | Pharmaceutical tablet composition comprising eltrombopag olamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3615007A1 true EP3615007A1 (en) | 2020-03-04 |
Family
ID=59350777
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17181421.3A Revoked EP3395331B1 (en) | 2017-04-26 | 2017-07-14 | Pharmaceutical tablet composition comprising eltrombopag olamine |
| EP18711260.2A Withdrawn EP3615007A1 (en) | 2017-04-26 | 2018-03-07 | Pharmaceutical tablet composition comprising eltrombopag olamine |
| EP22157319.9A Withdrawn EP4019009A1 (en) | 2017-04-26 | 2018-03-07 | Pharmaceutical tablet composition comprising eltrombopag olamine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17181421.3A Revoked EP3395331B1 (en) | 2017-04-26 | 2017-07-14 | Pharmaceutical tablet composition comprising eltrombopag olamine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22157319.9A Withdrawn EP4019009A1 (en) | 2017-04-26 | 2018-03-07 | Pharmaceutical tablet composition comprising eltrombopag olamine |
Country Status (4)
| Country | Link |
|---|---|
| EP (3) | EP3395331B1 (en) |
| AU (1) | AU2018257238A1 (en) |
| RU (1) | RU2019132494A (en) |
| WO (1) | WO2018197088A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3970700A1 (en) | 2020-09-16 | 2022-03-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | A solid oral pharmaceutical formulation comprising eltrombopag olamine |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020055364A2 (en) * | 2018-08-02 | 2020-03-19 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A pharmaceutical composition comprising eltrombopag olamine |
| CA3160779A1 (en) * | 2019-12-06 | 2021-06-10 | Synthon B.V. | Pharmaceutical composition comprising eltrombopag bis(monoethanolamine) |
| EP4069203A1 (en) | 2019-12-06 | 2022-10-12 | Synthon B.V. | Pharmaceutical composition comprising eltrombopag bis(monoethanolamine) |
| EP4188337A1 (en) * | 2020-07-31 | 2023-06-07 | KRKA, d.d., Novo mesto | Formulation containing dexketoprofen and tramadol and method for making the same |
| RU2769863C1 (en) * | 2020-10-08 | 2022-04-07 | Нестерук Владимир Викторович | Solid dosage form of avatrombopag and method for production thereof |
| CN114099435A (en) * | 2021-12-16 | 2022-03-01 | 南京威凯尔生物医药科技有限公司 | Esprop-pasolamine nano micelle and preparation method thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY2010012I2 (en) | 2000-05-25 | 2020-05-29 | Novartis Ag | THROMBOPOIETIN MIMETICS |
| MY142390A (en) | 2002-05-22 | 2010-11-30 | Glaxosmithkline Llc | 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| EP1622609A4 (en) | 2003-04-29 | 2008-09-03 | Smithkline Beecham Corp | Methods for treating degenerative diseases/injuries |
| ECSP077628A (en) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | NEW PHARMACEUTICAL COMPOSITION |
| TWI379681B (en) | 2009-04-01 | 2012-12-21 | Pliva Hrvatska D O O | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof |
| WO2012121957A1 (en) | 2011-03-08 | 2012-09-13 | Glaxosmithkline Llc | Combination |
| WO2015029074A2 (en) | 2013-09-02 | 2015-03-05 | Hetero Research Foundation | Compositions of eltrombopag |
| JP6481622B2 (en) | 2014-02-14 | 2019-03-13 | 富士通株式会社 | Palpation support device, palpation support method, and palpation support program |
-
2017
- 2017-07-14 EP EP17181421.3A patent/EP3395331B1/en not_active Revoked
-
2018
- 2018-03-07 EP EP18711260.2A patent/EP3615007A1/en not_active Withdrawn
- 2018-03-07 WO PCT/EP2018/055618 patent/WO2018197088A1/en not_active Ceased
- 2018-03-07 RU RU2019132494A patent/RU2019132494A/en not_active Application Discontinuation
- 2018-03-07 AU AU2018257238A patent/AU2018257238A1/en not_active Abandoned
- 2018-03-07 EP EP22157319.9A patent/EP4019009A1/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3970700A1 (en) | 2020-09-16 | 2022-03-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | A solid oral pharmaceutical formulation comprising eltrombopag olamine |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4019009A1 (en) | 2022-06-29 |
| AU2018257238A1 (en) | 2019-10-10 |
| RU2019132494A (en) | 2021-05-26 |
| WO2018197088A1 (en) | 2018-11-01 |
| EP3395331A1 (en) | 2018-10-31 |
| EP3395331B1 (en) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3409272B1 (en) | Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder | |
| WO2018197088A1 (en) | Pharmaceutical tablet composition comprising eltrombopag olamine | |
| AU756422B2 (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
| EP4103159A1 (en) | Omecamtiv mecarbil tablet | |
| EP3331501B1 (en) | Gastro-resistant formulation containing posaconazole | |
| CN102137663B (en) | The stable pharmaceutical preparation of suppression variable color | |
| AU2012357956A1 (en) | Immediate release multi unit pellet system | |
| WO2020165407A1 (en) | Afabicin formulation, method for making the same | |
| EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| US20090209587A1 (en) | Repaglinide formulations | |
| WO2010046932A2 (en) | Extended release pharmaceutical composition of minocycline and process thereof | |
| WO2005020998A1 (en) | Pharmaceutical compositions of moxifloxacin and processes for their preparation | |
| EP3210599B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
| US20160158157A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| US20080182908A1 (en) | Pharmaceutical compositions comprising memantine | |
| CA2174538A1 (en) | Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation | |
| WO2018130943A1 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
| JP2009538905A (en) | Stable formulation comprising moisture sensitive drug and method for producing the same | |
| WO2021116244A1 (en) | Modulation of drug release and bioavailability of compositions containing dolutegravir sodium and other anti hiv drugs | |
| GB2491205A (en) | Composition comprising bosentan and diluents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20191115 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 7/00 20060101AFI20210126BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/4152 20060101ALI20210226BHEP Ipc: A61P 1/00 20060101ALI20210226BHEP Ipc: A61P 7/00 20060101ALI20210226BHEP Ipc: A61K 9/20 20060101AFI20210226BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20210324 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 7/00 20060101ALI20210921BHEP Ipc: A61P 1/00 20060101ALI20210921BHEP Ipc: A61K 31/4152 20060101ALI20210921BHEP Ipc: A61K 9/20 20060101AFI20210921BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20211019 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| INTC | Intention to grant announced (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20220809 |